

**(12) PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 199529363 B2**  
**(10) Patent No. 701342**

(54) Title  
Reconstituted human antibody against human interleukin-8

(51)<sup>6</sup> International Patent Classification(s)  
C07K 016/24 C12N 015/62  
C12N 001/21 C12P 021/02  
C12N 015/13 C12P 021/08

(21) Application No: 199529363 (22) Application Date: 1995.07.12

(87) WIPO No: WO96/02576

(30) Priority Data

(31) Number	(32) Date	(33) Country
6-161481	1994.07.13	JP
6-289951	1994.11.24	JP
6-310785	1994.12.14	JP

(43) Publication Date : 1996.02.16  
(43) Publication Journal Date : 1996.03.28  
(44) Accepted Journal Date : 1999.01.28

(71) Applicant(s)  
Chugai Seiyaku Kabushiki Kaisha

(72) Inventor(s)  
Kouji Matsushima; Yoshihiro Matsumoto; Yoshiki Yamada; Koh Sato; Masayuki Tsuchiya ; Tatsumi Yamazaki

(74) Agent/Attorney  
DAVIES COLLISON CAVE

(56) Related Art  
KO ET AL, J. IMMUNOL. METH., 1992, 149: 227-235

OPI DATE 16/02/96 APPLN. ID 29363/95  
AOJP DATE 28/03/96 PCT NUMBER PCT/JP95/01396



AU9529363

<p>(51) 国際特許分類6</p> <p>C07K 16/24, C12N 15/13, 15/62, C12P 21/02, 21/08, C12N 1/21 // (C12P 21/02, C12R 1:19)</p>	<p>A1</p>	<p>(11) 国際公開番号 WO96/02576</p> <p>(43) 国際公開日 1996年2月1日(01.02.96)</p>								
<p>(21) 国際出願番号 PCT/JP95/01396</p> <p>(22) 国際出願日 1995年7月12日(12.07.95)</p> <p>(30) 優先権データ</p> <table border="0"><tr><td>特願平6/161481</td><td>1994年7月13日(13.07.94)</td><td>JP</td></tr><tr><td>特願平6/289951</td><td>1994年11月24日(24.11.94)</td><td>JP</td></tr><tr><td>特願平6/310785</td><td>1994年12月14日(14.12.94)</td><td>JP</td></tr></table> <p>(71) 出願人 (米国を除くすべての指定国について) 中外製薬株式会社 (CHUGAI SEIYAKU KABUSHIKI KAISHA)(JP/JP) 〒115 東京都北区浮間5丁目5番1号 Tokyo, (JP)</p> <p>(72) 発明者：および</p> <p>(75) 発明者／出願人 (米国についてのみ) 松島綱治(MATSUSHIMA, Kouji)(JP/JP) 〒921 石川県金沢市つつじが丘210-9 Ishikawa, (JP) 松本義弘(MATSUMOTO, Yoshihiro)(JP/JP) 山田良樹(YAMADA, Yoshiki)(JP/JP) 佐藤 功(SATO, Koh)(JP/JP) 土屋政幸(TSUCHIYA, Masayuki)(JP/JP)</p>	特願平6/161481	1994年7月13日(13.07.94)	JP	特願平6/289951	1994年11月24日(24.11.94)	JP	特願平6/310785	1994年12月14日(14.12.94)	JP	<p>山崎達夫(YAMAZAKI, Tatsuomi)(JP/JP) 〒412 静岡県御殿場市駒門1丁目135番地 中外製薬株式会社内 Shizuoka, (JP)</p> <p>(74) 代理人 弁護士 石田 敬, 外(ISHIDA, Takashi et al.) 〒105 東京都港区虎ノ門三丁目5番1号 虎ノ門37ビル 青和特許法律事務所 Tokyo, (JP)</p> <p>(81) 指定国 AM, AT, AU, DB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, KE, KG, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, 欧州特許(AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI特許(BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO特許(KE, MW, SD, SZ, UG)</p> <p>添付公開書類 [国際調査報告書]</p>
特願平6/161481	1994年7月13日(13.07.94)	JP								
特願平6/289951	1994年11月24日(24.11.94)	JP								
特願平6/310785	1994年12月14日(14.12.94)	JP								
<p>(54) Title: RECONSTITUTED HUMAN ANTIBODY AGAINST HUMAN INTERLEUKIN-8</p> <p>(54) 発明の名称 ヒトインターロイキン-8に対する再構成ヒト抗体</p> <p>(57) Abstract</p> <p>A reconstituted human antibody against human interleukin-8 (IL-8), comprising (A) L chains comprising: (1) the human L-chain C region, and (2) the L-chain V region containing the human L-chain FR and the L-chain CDR of a mouse monoclonal antibody against IL-8; and (B) H chains comprising: (1) the human H-chain C region, and (2) the H-chain V region containing the human H-chain FR and the H-chain CDR of a mouse monoclonal antibody against IL-8. As the major part of the reconstituted antibody derives from a human antibody and antigenicity of the CDR is low, this antibody has a low antigenicity against the human body, thus being expected to be applicable for medical therapy.</p>										

(57) 要約

(A) (1) ヒトL鎖C領域、及び

(2) ヒトL鎖FR、及びヒトIL-8に対するマウスモノクローナル抗体の；鎖CDRを含んでなるL鎖V領域、を含んで成るL鎖；並びに

(B) (i) ヒトH鎖C領域、及び

(2) ヒトH鎖FR、及びヒトIL-8に対するマウスモノクローナル抗体のH鎖CDRを含んで成るH鎖V領域を含んで成るH鎖；

を含んで成るヒトIL-8に対する再構成された抗体。

この再構成ヒト抗体の大部分がヒト抗体に由来し、そしてCDRは抗原性が低いことから、本発明の再構成ヒト抗体はヒトに対する抗原性が低く、そしてそれ故に医学療法用として期待される。

特許としての用途のみ

本特許は、以下に公開される国際出願をパンフレット第一頁にPCT加盟国を指定するために使用される。

AL	アルバニア	DK	デンマーク	LK	スリランカ	PT	ポルトガル
AM	アルメニア	DE	ドイツ	LR	リベリア	RO	ルーマニア
AT	オーストリア	ES	スペイン	LS	レソト	RU	ロシア連邦
AZ	アゼルバイジャン	FI	フィンランド	LT	リトアニア	SE	スウェーデン
BB	バハマ	FR	フランス	LU	ルクセンブルグ	SG	シンガポール
BE	ベルギー	GA	ガボン	LV	ラトヴィア	SI	スロベニア
BG	ブルガリア	GB	イギリス	MC	モナコ	SK	スロバキア共和国
BJ	ベナン	GE	グルジア	MD	モルドバ	SN	セネガル
BR	ブラジル	GR	ギリシャ	MG	マダガスカル	SZ	スワジランド
BY	ベラルーシ	HU	ハンガリー	MN	モンゴル	TD	チャド
CA	カナダ	IE	アイルランド	ML	マリ	TG	トーゴ
CF	中央アフリカ共和国	IT	イタリア	MR	モーリタニア	TJ	タジキスタン
CG	コンゴ	JP	日本	MW	マラウイ	TM	トルクメニスタン
CH	スイス	KE	ケニア	MX	メキシコ	TR	トルコ
CI	コートジボワール	KG	キルギスタン	NE	ニジェール	TT	トリニダード・トバゴ
CM	カメルーン	KR	韓国	NL	オランダ	UG	ウガンダ
CN	中国	KZ	カザフスタン	NO	ノルウェー	US	米国
CZ	チェコ	LI	リヒテンシュタイン	NZ	ニュージーランド	UZ	ウズベキスタン共和国
DE	ドイツ			PL	ポーランド	VN	ベトナム

ABSTRACT

The present invention discloses a reshaped human antibody against human IL-8 comprising:

5 (A) L chains each comprising:

(1) a human L chain C region; and,

(2) an L chain V region comprising a human L chain FR, and an L chain CDR of mouse monoclonal antibody against human IL-8; and,

10 (B) H chains each comprising:

(1) a human H chain C region; and,

(2) an H chain V region comprising a human H chain FR, and an H chain CDR of mouse monoclonal antibody against human IL-8.

15 Since the majority of this reshaped human antibody originates in human antibody and the CDR has low antigenicity, the reshaped human antibody of the present invention has low antigenicity to humans, and can therefore be expected to be useful in medical  
20 treatment.



## SPECIFICATION

## Reshaped Human Antibody to Human Interleukin-8

## TECHNICAL FIELD

5       The present invention relates to the complementarity determining regions (CDRs) and the variable regions (V regions) of mouse monoclonal antibody against human interleukin-8 (IL-8), to human/mouse chimeric antibody against human IL-8, as well as to a reshaped human antibody  
10       wherein the complementarity determining regions of the human light chain (L chain) variable region and the human heavy chain (H chain) variable region are substituted with the CDR of mouse monoclonal antibody against human IL-8. Moreover, the present invention provides DNAs that code for  
15       the above-mentioned antibody and its portions. The present invention also relates to a vector that contains the above-mentioned DNA, and more particularly, to an expression vector and a host transformed with said vector. Moreover, the present invention provides a process for producing  
20       reshaped human antibody against human IL-8 as well as a process for producing a chimeric antibody against human IL-8.

## BACKGROUND ART

25       Interleukin-8 (IL-8) was discovered in the culture supernatant of monocytes stimulated with lipopolysaccharide (LPS), and is a chemokine known also as monocyte-derived neutrophil chemotactic factor (MDNCF) or neutrophil activating protein-1 (NAP-1). IL-8 is produced by various cells, acts on polymorphonuclear leukocytes and  
30       lymphocytes, and possesses activity that causes chemotaxis along its concentration gradient. In addition, not only does it induce chemotaxis in neutrophils, but it also activates neutrophilic functions such as degranulation, the release of superoxide, and the promotion of adhesion to  
35       endothelial cells.

In inflammatory diseases, and more specifically in respiratory diseases such as pulmonary cystic fibrosis,



idiopathic pulmonary fibrosis, adult respiratory distress syndrome, sarcoidosis and empyema, as well as in skin diseases such as psoriasis, and in chronic rheumatoid arthritis, Crohn's disease and ulcerative colitis,

5 leukocyte infiltration is observed pathologically at the inflamed site of these diseases. In addition, IL-8 is detected in test samples from patients with these diseases, suggesting that IL-8 may play a central role in inflammation. (McElvaney, N.G. et al., J. Clin. Invest., 10 90, 1296-1301, 1992; Lynch III, J.P. et al., Am. Rev. Respir. Dis., 145, 1433-1439, 1992; Donnelly, S.C. et al., Lancet, 341, 643-647, 1993; Car, B.D. et al., Am. J. Respir. Crit. Care Med., 149, 655-659, 1994; Antony, V.B. et al., J. Immunol., 151, 7216-7223, 1993; Takematsu, H. et al., Arch. Dermatol., 129, 74-80, 1993; Brennan, F.M. et al., Eur. J. Immunol., 20, 2141-2144, 1990; Izzo, R.S. et al., Scand. J. Gastroenterol., 28, 296-300, 1993; Izzo, R.S. et al., Am. J. Gastroenterol., 87, 1447-1452, 1992).

Subsequence to immunizing mice with human IL-8 as antigen, Ko, Y-C. et al. prepared the mouse monoclonal antibody WS-4 that binds to human IL-8 and inhibits the binding of human IL-8 to neutrophils as a result of that binding, namely that neutralizes the biological activity possessed by human IL-8. It has been clearly shown that 25 the isotypes of mouse monoclonal antibody WS-4 consist of a K-type L chain and a C $\gamma$ 1-type H chain (J. Immunol. Methods, 149, 227-235, 1992).

Known examples of antibodies against human IL-8 other than WS-4 include A.5.12.14 (Boylan, A.M. et al., J. Clin. Invest., 89, 1257-1267, 1992), the anti-Pep-1 antibody and anti-Pep-3 antibody disclosed in International Patent Application No. WO92-04372, and DM/C7 (Mulligan, M.S. et al., J. Immunol., 150, 5585-5595, 1993).

It was also found by administration of the mouse 35 monoclonal antibody WS-4 into experimental models using rabbits that neutrophil infiltration is inhibited in pulmonary ischemic and reperfusion injury (Sekido, N. et



al., Nature, 365, 654-657, 1993), LPS-induced dermatitis (Harada, A. et al., Internatl. Immunol., 5, 681-690, 1993) and LPS- or interleukin-1 (IL-1)-induced arthritis (Akahoshi, T. et al., Lymphokine Cytokine Res., 13, 113-116, 1994).

5 A homologue of human IL-8 exists in rabbits, and is referred to as rabbit IL-8. Since it has been clearly shown that the mouse monoclonal antibody WS-4 cross-reacts with rabbit IL-8, and that the antibody inhibits binding of rabbit IL-8 to rabbit neutrophils (Harada, A. et al., Internatl. Immunol., 5, 681-690, 1993), these findings suggest that anti-human IL-8 antibody would be useful as a therapeutic agent for the treatment of inflammatory diseases in humans.

10 Monoclonal antibodies originating in mammals other than humans exhibit a high degree of immunogenicity (also referred to as antigenicity) in humans. For this reason, even if mouse antibody is administered to humans, as a result of its being metabolized as a foreign substance, the half life of mouse antibody in humans is relatively short, thus preventing its anticipated effects from being adequately demonstrated. Moreover, human anti-mouse antibody that is produced in response to administered mouse antibody causes an immune response that is both

20 uncomfortable and dangerous for the patient, examples of which include serum sickness or other allergic response. For this reason, mouse antibody cannot be administered frequently to humans.

25 In order to resolve these problems, a process for producing a humanized antibody was developed. Mouse antibody can be humanized by two methods. The simpler method involves producing a chimeric antibody in which the variable region (V region) is derived from the original mouse monoclonal antibody, and the constant region (C region) is derived from a suitable human antibody. Since the resulting chimeric antibody contains the variable region of the mouse antibody in its complete form, it has

30

35



identical specificity to the original mouse antibody, and can be expected to bind to antigen.

Moreover, in the chimeric antibody, since the proportion of protein sequences derived from an animal other than human is substantially reduced in comparison to the original mouse antibody, it is predicted to have less immunogenicity in comparison to the original mouse antibody. Although the chimeric antibody binds well to antigen and has low immunogenicity, there is still the possibility of an immune response to the mouse variable region occurring, however (LoBuglio, A.F. et al., Proc. Natl. Acad. Sci. USA, 86, 4220-4224, 1989).

Although the second method for humanizing mouse antibody is more complexed, the latent immunogenicity of the mouse antibody is reduced considerably. In this method, only the complementarity determining region (CDR) is grafted from the variable region of mouse antibody onto the human variable region to create a reshaped human variable region. However, in order to approximate more closely the structure of the CDR of the reshaped human variable region to the structure of the original mouse antibody, there are cases in which it may be necessary to graft a portion of the protein sequence of the framework region (FR) supporting the CDR from the variable region of the mouse antibody to the human variable region.

Next, these reshaped human variable regions are linked to the human constant region. Those portions derived from non-human protein sequences consist only of the CDR and a very slight portion of the FR in the humanized antibody. CDR is composed of hyper-variable protein sequences, and these do not exhibit species specificity. For this reason, the reshaped human antibody that contains the mouse CDRs ought not to have immunogenicity stronger than that of a natural human antibody containing human CDRs.

Additional details regarding reshaped human antibodies can be found by referring to Riechmann, L. et al., Nature, 332, 323-327, 1988; Verhoeyen, M. et al., Science, 239,



1534-1536, 1988; Kettleborough, C.A. et al., Protein Eng.,  
4, 773-783, 1991; Maeda, H. et al., Hum. Antibodies  
Hybridomas, 2, 124-134, 1991; Gorman, S.D. et al., Proc.  
Natl. Acad. Sci. USA, 88, 4181-4185, 1991; Tempest, P.R. et  
5 al., Bio/Technology, 9, 266-271, 1991; Co, M.S. et al.,  
Proc. Natl. Acad. Sci. USA, 88, 2869-2873, 1991; Carter, P.  
et al., Proc. Natl. Acad. Sci. USA, 89, 4285-4289, 1992;  
Co, M.S. et al., J. Immunol., 148, 1149-1154, 1992; and,  
Sato, K. et al., Cancer Res., 53, 851-856, 1993.

10 DISCLOSURE OF THE INVENTION

As stated above, although reshaped human antibodies  
are predicted to be useful for the purpose of therapy,  
there are no known reshaped human antibodies against human  
IL-8. Moreover, there are no standard processes that can  
15 be applied universally to an arbitrary antibody for  
producing reshaped human antibody. Thus, various  
contrivances are necessary to create a reshaped human  
antibody that exhibits sufficient binding activity and/or  
neutralizing activity with respect to a specific antigen  
20 (for example, Sató, K. et al., Cancer Res., 53, 851-856,  
1993). The present invention provides an antibody against  
human IL-8 having a low degree of immunogenicity.

The present invention provides a reshaped human  
antibody against human IL-8. The present invention also  
25 provides a human/mouse chimeric antibody that is useful in  
the production process of said reshaped human antibody.  
Moreover, the present invention also provides a fragment of  
reshaped human antibody. In addition, the present  
invention provides an expression system for producing  
30 chimeric antibody and reshaped human antibody and fragments  
thereof. Moreover, the present invention also provides a  
process for producing chimeric antibody against human IL-8  
and fragments thereof, as well as a process for producing  
reshaped human antibody against human IL-8 and fragments  
35 thereof.

More specifically, the present invention provides:



(1) an L chain V region of mouse monoclonal antibody against human IL-8; and,

(2) an H chain V region of mouse monoclonal antibody against human IL-8.

5       Moreover, the present invention provides:

(1) an L chain comprising a human L chain C region, and an L chain V region of mouse monoclonal antibody against human IL-8; and,

10       (2) an H chain comprising a human H chain C region, and an H chain V region of mouse monoclonal antibody against human IL-8.

Moreover, the present invention also provides chimeric antibody against human IL-8 comprising:

15       (1) L chains each comprising a human L chain C region, and an L chain V region of mouse monoclonal antibody against human IL-8; and,

(2) H chains each comprising a human H chain C region, and an H chain V region of mouse monoclonal antibody against human IL-8.

20       Moreover, the present invention provides:

(1) an L chain V region of mouse monoclonal antibody WS-4 against human IL-8; and,

(2) an H chain V region of mouse monoclonal antibody WS-4 against human IL-8.

25       Moreover, the present invention also provides:

(1) an L chain comprising a human L chain C region, and an L chain V region of mouse monoclonal antibody WS-4 against human IL-8; and,

30       (2) an H chain comprising a human H chain C region, and an H chain V region of mouse monoclonal antibody WS-4 against human IL-8.

In addition, the present invention provides chimeric antibody against human IL-8 comprising:

35       (1) L chains each comprising a human L chain C region, and an L chain V region of mouse monoclonal antibody WS-4 against human IL-8; and,



(2) H chains each comprising a human H chain C region, and an H chain V region of mouse monoclonal antibody WS-4 against human IL-8.

Moreover, the present invention provides:

5 (1) CDR of an L chain V region of monoclonal antibody against human IL-8; and,

(2) CDR of an H chain V region of monoclonal antibody against human IL-8.

Moreover, the present invention also provides:

10 (1) CDR of an L chain V region of mouse monoclonal antibody against human IL-8; and,

(2) CDR of an H chain V region of mouse monoclonal antibody against human IL-8.

Moreover, the present invention also provides a  
15 reshaped human L chain V region of an antibody against human IL-8 comprising:

(1) framework regions (FRs) of a human L chain V region; and,

20 (2) CDRs of an L chain V region of mouse monoclonal antibody against human IL-8;

as well as a reshaped human H chain V region of antibody against human IL-8 comprising:

(1) FRs of a human H chain V region; and,

(2) CDRs of an H chain V region of mouse monoclonal  
25 antibody against human IL-8.

Moreover, the present invention provides a reshaped human L chain of antibody against human IL-8 comprising:

(1) a human L chain C region; and,

30 (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody against human IL-8;

as well as a reshaped human H chain of antibody against human IL-8 comprising:

(1) a human H chain C region; and,

35 (2) an H chain V region comprising human H chain FRs and H chain CDRs of mouse monoclonal antibody against human IL-8.



In addition, the present invention also provides reshaped human antibody against human IL-8 comprising:

(A) L chains each comprising:

- 5 (1) a human L chain C region; and,  
(2) an L chain V region comprising FRs of a human L chain, and CDRs of an L chain of mouse monoclonal antibody against human IL-8; as well as

(B) H chains each comprising:

- 10 (1) a human H chain C region; and,  
(2) an H chain V region comprising FRs of a human H chain, and CDRs of an H chain of mouse monoclonal antibody against human IL-8.

More specifically, the present invention provides:

- 15 (1) CDRs of an L chain V region of mouse monoclonal antibody WS-4 against human IL-8 having the following sequences or a portion thereof:

CDR1: Arg Ala Ser Glu Ile Ile Tyr Ser Tyr Leu Ala

CDR2: Asn Ala Lys Thr Leu Ala Asp

CDR3: Gln His His Phe Gly Phe Pro Arg Thr

20 as well as

- (2) CDRs of an H chain V region of mouse monoclonal antibody WS-4 against human IL-8 having the following sequences or a portion thereof:

CDR1: Asp Tyr Tyr Leu Ser

( 25 CDR2: Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu  
Tyr Ser Ala Ser Val Lys Gly

CDR3: Glu Asn Tyr Arg Tyr Asp Val Glu Leu Ala Tyr

Moreover, the present invention provides a reshaped human L chain V region of antibody against human IL-8  
30 comprising:

- (1) framework regions (FRs) of a human L chain V region; and,

- (2) CDRs of an L chain V region of mouse monoclonal antibody WS-4 against human IL-8; as well as  
35 a reshaped human H chain V region of antibody against human IL-8 comprising:

- (1) FRs of a human H chain V region; and,



(2) CDRs of an H chain V region of monoclonal antibody WS-4 against human IL-8.

Moreover, the present invention provides a reshaped human L chain of antibody against human IL-8 comprising:

- 5 (1) a human L chain C region; and,  
(2) an L chain V region comprising FRs of a human L chain, and CDRs of an L chain of mouse monoclonal antibody WS-4 against human IL-8; as well as  
a reshaped human H chain of antibody against human IL-8 comprising:

- 10 (1) a human H chain C region; and,  
(2) an H chain V region comprising FRs of a human H chain, and CDRs of an H chain of monoclonal antibody WS-4 against human IL-8.

15 In addition, the present invention also provides a reshaped human antibody against human IL-8 comprising:

- (A) L chains each comprising:  
(1) a human L chain C region; and,  
(2) an L chain V region comprising FRs of a  
20 human L chain and CDRs of an L chain of mouse monoclonal antibody WS-4 against human IL-8; and  
(B) H chains each comprising:  
(1) a human H chain C region; and,  
(2) an H chain V region comprising FRs of a  
25 human H chain and CDRs of an H chain of mouse monoclonal antibody WS-4 against human IL-8.

Examples of the above-mentioned FRs of a human L chain include those having the following amino acid sequences or a portion thereof:

30 FR1: Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser  
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys

FR2: Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu  
Leu Ile Tyr

35 FR3: Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly  
Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile  
Ala Thr Tyr Tyr Cys

FR4: Phe Gly Gln Gly Thr Lys Val Glu Ile Lys



or,

FR1: Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser  
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys

FR2: Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu  
5 Leu Ile Tyr

FR3: Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly  
Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile  
Ala Thr Tyr Tyr Cys

FR4: Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

10 Examples of the above-mentioned FRs of a human H chain  
include those having the following amino acid sequences or  
a portion thereof:

FR1: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val  
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe  
15 Thr Phe Ser

FR2: Trp Val Arg Gln Ala Gln Gly Lys Gly Leu Glu Leu  
Val Gly

FR3: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu Ala Val  
20 Tyr Tyr Cys Ala Arg

FR4: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

FR1: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val  
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe  
Thr Phe Ser

FR2: Trp Val Arg Gln Ala Gln Gly Lys Gly Leu Glu Trp  
25 Val Gly

FR3: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu Ala Val  
Tyr Tyr Cys Ala Arg

FR4: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

FR1: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val  
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe  
Thr Phe Ser

FR2: Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu  
35 Val Gly



FR3: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu Ala Val  
Tyr Tyr Cys Ala Arg

FR4: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

5 FR1: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val  
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe  
Thr Phe Ser

FR2: Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp  
Val Gly

10 FR3: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu Ala Val  
Tyr Tyr Cys Ala Arg

FR4: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

15 FR1: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val  
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe  
Thr Phe Ser

FR2: Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp  
Val Gly

20 FR3: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu Ala Val  
Tyr Tyr Cys Ala Arg

FR4: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

( 25 FR1: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val  
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe  
Thr Phe Ser

FR2: Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp  
Val Gly

30 FR3: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu Ala Val  
Tyr Tyr Cys Ala Arg

FR4: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

FR1: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val  
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe  
Thr Phe Ser

35 FR2: Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp  
Val Gly



FR3: Arg Phe Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu Ala Val  
Tyr Tyr Cys Ala Arg

FR4: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser; or,

5 FR1: Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val  
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe  
Thr Phe Ser

FR2: Trp Val Arg Gln Ala Gln Gly Lys Gly Leu Glu Trp  
Val Gly

10 FR3: Arg Phe Thr Ile Ser Arg Glu Asp Ser Lys Asn Thr  
Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu Ala Val  
Tyr Tyr Cys Ala Arg

FR4: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

15 In addition, the present invention also relates to DNA  
that codes for polypeptide that comprises the above-  
mentioned various antibodies, and their fragments. The  
present invention also relates to a vector that contains  
the above-mentioned DNA, an example of which is an  
expression vector. Moreover, the present invention  
20 provides a host that is transformed by the above-mentioned  
vector.

Moreover, the present invention also provides a  
process for producing chimeric antibody against human IL-8,  
and its fragments, as well as a process for producing  
25 reshaped human antibody against human IL-8, and its  
fragments.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 indicates the expression vectors HEF-VL-gK and  
HEF-VH-gY1, containing the human elongation factor-1 $\alpha$  (HEF-  
30 1 $\alpha$ ) promoter/enhancer, which are useful for expression of  
the L chain and H chain, respectively, of the antibody of  
the present invention.

Fig. 2 is a graph indicating the results of ELISA for  
confirmation of the binding ability to human IL-8 of the  
35 chimeric WS-4 antibody (chL/chH) of the present invention  
secreted into the culture medium of COS cells.



Fig. 3 is a diagram of the construction of DNA that codes for the amino acid sequences of each of the first version "a" (RVHa) of the H chain V region of reshaped human WS-4 antibody of the present invention (A), and the first version "a" (RVLa) of the L chain V region of reshaped human WS-4 antibody (B).

Fig. 4 is a graph indicating the results of ELISA for comparing the binding ability to human IL-8 of the L chain V region (RVLa) and the H chain V region (RVHa) of the reshaped human WS-4 antibody of the present invention in combination with, respectively, the H chain V region of chimeric WS-4 antibody (chH) and the L chain V region of chimeric WS-4 antibody (chL) expressed in COS cells, with that of the chimeric WS-4 antibody (chL/chH) of the present invention secreted into the culture medium of COS cells.

Fig. 5 is a graph indicating the results of ELISA for comparing the binding ability against human IL-8 of 8 types of reshaped human WS-4 antibody containing the RVLa of the present invention (RVLa/RVHa, RVLa/RVHb, RVLa/RVHc, RVLa/RVHd, RVLa/RVHe, RVLa/RVHf, RVLa/RVHg and RVLa/RVHh) secreted into the culture medium of COS cells, with that of the chimeric WS-4 antibody (chL/chH) of the present invention secreted into the culture medium of COS cells.

Fig. 6 is a graph indicating the results of ELISA for comparing the binding ability to human IL-8 of 8 types of reshaped human WS-4 antibody containing the second version RVLb of the present invention (RVLb/RVHa, RVLb/RVHb, RVLb/RVHc, RVLb/RVHd, RVLb/RVHe, RVLb/RVHf, RVLb/RVHg and RVLb/RVHh) produced in the culture supernatant of COS cells, with that of the chimeric WS-4 antibody (chL/chH) of the present invention secreted into the culture medium of COS cells.

Fig. 7 is a graph indicating the results of ELISA for comparing the binding abilities to human IL-8 of the purified reshaped human WS-4 antibodies RVLa/RVHg and RVLb/RVHg of the present invention and the purified chimeric WS-4 antibody (chL/chH) of the present invention.



Fig. 8 is a graph indicating the results of ligand receptor binding inhibition assays for comparison of the ability to inhibit binding of IL-8 to the IL-8 receptor, of the purified reshaped human antibodies RVLb/RVHg and RVLb/RVHg of the present invention, with that of the mouse WS-4 antibody and the chimeric WS-4 antibody (chL/chH) of the present invention.

SPECIFIC MODE FOR CARRYING OUT THE INVENTION

Cloning of DNA Coding for Mouse V Region

In order to clone a gene that codes for the V region of mouse monoclonal antibody against human IL-8, it is necessary to prepare a hybridoma that produces mouse monoclonal antibody against human IL-8 for the acquisition of such a gene. After the extraction of mRNA from the hybridoma, the mRNA is converted into single-stranded cDNA according to known methods, followed by amplification of the target DNA using the polymerase chain reaction (PCR) to obtain the gene. An example of a source of this gene is the hybridoma WS-4, which produces mouse monoclonal antibody against human IL-8, produced by Ko, Y.C. et al. The process for preparing this hybridoma is described in J. Immunol. Methods, 149, 227-235, 1992, and is described later as Reference Example 1.

(1) Extraction of Total RNA

In order to clone the target DNA that codes for the V region of mouse monoclonal antibody against human IL-8, total RNA can be obtained by disrupting the hybridoma cells by guanidine thiocyanate treatment and performing cesium chloride density gradient centrifugation (Chirgwin, J.M. et al., Biochemistry, 18, 5294-5299, 1979). Furthermore, other methods that are used during the cloning of genes, such as that in which detergent treatment and phenol treatment are performed in the presence of a ribonuclease (RNase) inhibitor such as vanadium complex (Berger, S.L. et al., Biochemistry, 18, 5143-5149, 1979), can also be used.

(2) cDNA Synthesis



Next, single-stranded cDNA complementary to mRNA can be obtained by treating the total RNA with reverse transcriptase using oligo(dT), an oligonucleotide complementary to the poly (A) tail located at the 3' end of mRNA, as primer, and the mRNA contained in the total RNA obtained in the above manner as template (Larrick, J.W. et al., Bio/Technology, 7, 934-938, 1989). In addition, a random primer may also be used at the same time. Furthermore, in the case that it is desired first to isolate mRNA, this may be done by applying the total RNA to a column of oligo(dT)-cellulose, to which the poly(A) tail of mRNA binds.

(3) Amplification of DNA Coding for V Region by Polymerase Chain Reaction

Next, cDNA that codes for the above-mentioned V region is specifically amplified using the polymerase chain reaction (PCR). In order to amplify the kappa (K) type L chain V region of mouse monoclonal antibody, the 11 types of oligonucleotide primers shown in SEQ ID Nos: 1 to 11 (Mouse Kappa Variable; MKV) and the oligonucleotide primer shown in SEQ ID No: 12 (Mouse Kappa Constant; MKC) are used as the 5' terminal primer and the 3' terminal primer, respectively. The above-mentioned MKV primers hybridize to the DNA sequence that codes for the mouse kappa-type L chain leader sequence, while the above-mentioned MKC primer hybridizes to the DNA sequence that codes for the mouse kappa-type L chain C region.

In order to amplify the H chain V region of mouse monoclonal antibody, the 12 types of oligonucleotide primers shown in SEQ ID Nos: 13 to 24 (Mouse Heavy Variable; MHV) and the oligonucleotide primer shown in SEQ ID No: 25 (Mouse Heavy Constant; MHC) are used as the 5' terminal primer and the 3' terminal primer, respectively. The above-mentioned MHV primers hybridize to the DNA sequence that codes for the mouse H chain leader sequence, while the above-mentioned MHC primer hybridizes to the DNA sequence that codes for the mouse H chain C region.



Furthermore, all 5' terminal primers (MKV and MHV) contain the sequence GTCGAC that provides a SalI restriction enzyme cleavage site near the 3' terminus, while both 3'-terminal primers (MKC and MHC) contain the nucleotide sequence CCCGGG that provides an XmaI restriction enzyme cleavage site near the 5' terminus. These restriction enzyme cleavage sites are used for the subcloning of target DNA fragments that code for both V regions into the respective cloning vectors. In the case that these restriction enzyme cleavage sites are also present in the target DNA sequence that codes for both V regions, other restriction enzyme cleavage sites should be used for subcloning into the respective cloning vectors.

(4) Isolation of DNA Coding for V Region

Next, in order to obtain the DNA fragment that codes for the target V region of mouse monoclonal antibody, the PCR amplification products are separated and purified on a low melting-point agarose gel or by a column [PCR Product Purification kit (QIAGEN PCR Purification Spin Kit: QIAGEN); DNA purification kit (GENECLEAN II, BIO101)]. A DNA fragment is obtained that codes for the target V region of mouse monoclonal antibody by enzyme treatment of the purified amplification product with the restriction enzymes SalI and XmaI.

Further, by cleaving a suitable cloning vector, like plasmid pUC19, with the same restriction enzymes, SalI and XmaI, and enzymatically linking the above-mentioned DNA fragment to this pUC19, a plasmid is obtained which contains a DNA fragment that codes for the target V region of mouse monoclonal antibody. Determination of the sequence of the cloned DNA can be performed in accordance with any routine method, an example of which is the use of an automated DNA sequencer (Applied Biosystems). Cloning and sequence determination of the target DNA are described in detail in Examples 1 and 2.

Complementarity Determining Regions (CDRs)



The present invention also provides hyper-V region or complementarity determining region (CDR) of the V region of mouse monoclonal antibody against human IL-8. V regions of both the L chain and H chain of the antibody form an antigen binding site. These regions on the L chain and the H chain have a similar basic structure. The V regions of both chains contain four framework regions for which the sequence is relatively conserved, and these four framework regions are linked by three hyper-V regions or CDR (Kabat, E.A. et al, "Sequences of Proteins of Immunological Interest", US Dept. Health and Human Services, 1991).

The majority of the portions of the above-mentioned four framework regions (FR) have a  $\beta$ -sheet structure, and the three CDRs form loops. The CDRs may form a portion of the  $\beta$  sheet structure in some cases. The three CDRs are maintained at extremely close positions three-dimensionally by the FRs, and contribute to formation of the antigen binding site together with three paired CDRs. The present invention provides CDRs that are useful as components of humanized antibody, as well as the DNA that codes for them. These CDRs can be determined from the experimental rules of Kabat, E.A. et al. "Sequences of Proteins of Immunological Interest", by comparing V region sequences with known amino acid sequences of the V region, a detailed explanation of which is provided in Embodiment 3.

#### Preparation of Chimeric Antibody

Prior to designing a reshaped human V region of antibody against human IL-8, it is necessary to confirm whether the CDRs used actually form an antigen-binding region. Chimeric antibody was prepared for this purpose. In order to prepare chimeric antibody, it is necessary to construct DNA that codes for the L chain and the H chain of chimeric antibody.. The basic method for constructing both DNA involves linking the respective DNA sequences of the mouse leader sequence observed in PCR-cloned DNA and the mouse V region sequence to a DNA sequence that codes for



human C region already present in a mammalian cell expression vector.

5 The above-mentioned human antibody C regions can be any human L chain C region and any human H chain C region, and with respect to the L chain, examples include human L chain C $\kappa$  or C $\lambda$ , while with respect to the H chain if IgG, examples include C $\gamma$ 1, C $\gamma$ 2, C $\gamma$ 3 or C $\gamma$ 4 (Ellison, J. et al., DNA, 1, 11-18 (1981), Takahashi, N. et al., Cell, 29, 671-679 (1982), Krawinkel, U. et al., EMBO J., 1, 403-407 (1982)), or other isotypes.

10 Two types of expression vectors are prepared for production of chimeric antibody, namely, an expression vector that contains DNA that codes for mouse L chain V region and human L chain C region under the control of an enhancer/promoter expression control region, and an  
15 expression vector that contains DNA that codes for mouse H chain V region and human H chain C region under the control of an enhancer/promoter type of expression control region. Next, host cells such as mammalian cells are simultaneously  
20 transformed by both of these expression vectors, and the transformed cells are cultured either in vitro or in vivo to produce chimeric antigen (e.g. WO91-16928).

Alternatively, DNA that codes for mouse L chain V region and human L chain C region and DNA that codes for  
25 mouse H chain V region and human H chain C region can be introduced into a single expression vector, host cells are transformed using said vector, and are then cultured either in vitro or in vivo to produce chimeric antibody.

The production of chimeric antibody from monoclonal  
30 antibody WS-4 is described in Embodiment 4.

cDNA that codes for mouse WS-4 K-type L chain leader sequence and the V region is cloned using PCR, and linked to an expression vector that contains human genome DNA that codes for the human L chain C $\kappa$  region. Similarly, cDNA  
35 that codes for the H chain leader sequence and V region of mouse WS-4 antibody is cloned using PCR and linked to an



expression vector that contains human genome DNA that codes for human C $\gamma$ 1 region.

5 More specifically, suitable nucleotide sequences are introduced at the 5' and 3' termini of cDNAs that code for the V regions of mouse WS-4 antibody using specially designed PCR primers so that (1) they can be easily inserted into the expression vector, and (2) they function suitably in said expression vector (for example, transcription efficiency is improved by introducing a Kozak  
10 sequence in the present invention).

Next, DNA that codes for the V region of mouse WS-4 antibody obtained by amplification by PCR using these primers is introduced into HEF expression vector (see Fig. 1) that already contains the desired human C region. These  
15 vectors are suitable for transient or stable expression of antibody genetically engineered in various mammalian cell systems.

When the antigen-binding activity of the chimeric WS-4 antibody prepared in this manner was tested, the chimeric  
20 WS-4 antibody demonstrated binding activity to human IL-8 (see Fig. 2). Thus, it was concluded that the correct mouse V region had been cloned, and the correct sequence had been determined.

Design of Reshaped Human WS-4 Antibody

25 In order to prepare a reshaped human antibody in which the CDRs of mouse monoclonal antibody are grafted onto human antibody, it is desirable that there be a high degree of homology between the amino acid sequences of the FRs of the mouse monoclonal antibody having the CDRs to be  
30 grafted, and the amino acid sequences of the FRs of the human monoclonal antibody into which the CDRs are to be grafted.

For this purpose, the human V regions to serve as the basis for designing the V regions of the reshaped human WS-  
35 4 antibody can be selected by comparing the amino acid sequences of the FRs of the mouse monoclonal antibody with the amino acid sequence of the FR of the human antibodies.



More specifically, the V regions of the L and H chains of mouse WS-4 antibody were compared with all known human V regions found in the database of the National Biomedical Research Foundation (NBRF) using the genetic analytical software, GENETEX (Software Development Co., Ltd.).

In a comparison with known human L chain V regions, the L chain V region of mouse WS-4 antibody was found to resemble most closely that of human antibody HAU (Watanabe, S. et al., Hoppe-Seyler's Z. Physiol. Chem., 351, 1291-1295, 1970), having homology of 69.2%. On the other hand, in a comparison with known human antibody H chain V regions, the H chain V region of WS-4 antibody was found to resemble most closely that of human antibody VDH26 (Buluwela, L. et al., EMBO J., 7, 2003-2010, 1988), having homology of 71.4%.

In general, homology of the amino acid sequences of mouse V regions to the amino acid sequences of human V regions is less than the homology to amino acid sequences of mouse V regions. This indicates that the V region of mouse WS-4 antibody does not completely resemble the human V region, and at the same time, indicates that humanization of mouse WS-4 V region is the best way to solve the problem of immunogenicity in human patients.

The V region of mouse WS-4 antibody was further compared with the consensus sequence of human V region subgroup defined by Kabat, E.A. et al., (1991), Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office, to compare between V region FR. Those results are shown in Table 1.



Table 1 Homology (%) Between FR of Mouse WS-4 V Region  
and FR of the Consensus Sequence of the Human V Regions of  
Various Subgroups

A. FR in L Chain V Region			
HSGI	HSGII	HSGIII	HSGIV
64.4	51.3	57.3	57.5
B. FR in H Chain V Region			
HSGI	HSGII	HSGIII	
46.9	40.9	62.3	

5

The FRs of the L chain V region of mouse WS-4 antibody most closely resembled the consensus sequence of FR of the human L chain V region subgroup I (HSGI), having homology of 64.4%. On the other hand, the FRs of the H chain V region of mouse WS-4 antibody most closely resembled the consensus sequence of human H chain V region subgroup III (HSGIII), having homology of 62.3%.

10

These results support the results obtained from the comparison with known human antibodies, the L chain V region of human antibody HAU belonging to human L chain V region subgroup I, and the H chain V region of human antibody VDH26 belonging to human H chain V region subgroup III. In order to design the L chain V region of reshaped human WS-4 antibody, it is probably best to use a human L chain V region belonging to subgroup I (HSGI), while in order to design the H chain V region of reshaped human WS-4 antibody, it is probably best to use the H chain V region of a human antibody belonging to subgroup III (HSGIII).

15

20

In a comparison with the L chain V region of known human antibodies, the L chain V region of mouse antibody WS-4 most closely resembled the L chain V region of human antibody REI, a member of subgroup I of human L chain V region. Thus, the FR of REI were used in designing the L chain V region of reshaped human WS-4 antibody. Within these human FR based on REI, there are differences in five amino acids (at positions 39, 71, 104, 105 and 107; see

25

30



Table 2) in comparison with the human REI documented in the original literature (Palm, W. et al., Hoppe-Seyler's Z. Physiol. Chem., 356, 167-191, 1975; and, Epp, O. et al., Biochemistry, 14, 4943-4952, 1975).

5       The amino acid numbers shown in the table are based on the experience of Kabat, E.A. et al. (1991). The changes in the two amino acids at positions 39 and 71 were same changes caused by the amino acids present in the FR of the L chain V region of rat CAMPATH-1H antibody (Riechmann, et  
10       al., 1988). According to Kabat, et al. (1991), the changes in the other three amino acids in FR4 (positions 104, 105 and 107) are based on the J region from other human KL chains, and do not deviate from humans.

15       Two versions of the L chain V region of reshaped human WS-4 antibody were designed. In the first version RVL<sub>a</sub>, FR was identical to the FR based on REI present in reshaped human CAMPATH-1H antibody (Riechmann, et al., 1988), while the CDR was identical to the CDR in the L chain V region of  
20       mouse WS-4 antibody. The second version, RVL<sub>b</sub>, was based on RVL<sub>a</sub>, and differed only by one amino acid at position 71 in human FR3. As defined by Chothia, C. et al., J. Mol. Biol., 196, 901-917, 1987, residue 71 is a portion of the canonical structure of the CDR1 of the L chain V region.

25       Amino acid at this position is predicted to directly affect the structure of the CDR1 loop of the L chain V region, and for this reason, it considered to have a significant effect on antigen binding. In RVL<sub>b</sub> of the L chain V region of reshaped human WS-4 antibody, the phenylalanine at position 71 is changed to tyrosine. Table  
30       2 shows the respective amino acid sequences of the L chain V region of mouse WS-4 antibody, the FR of the modified REI for use in reshaped human CAMPATH-1H antibody (Riechmann, et al., 1988) and the two versions of the L chain V region of reshaped human WS-4 antibody.



Table 2 Design of L Chain V Region of Reshaped Human WS-4

	1	2	3	4
	12345678901234567890123	45678901234	567890123456789	
WS-4L	DIQMTQSPASLSASVGETVTITC	RASEIIYSYLA	WYQQKQKGKSPOLLVY	
REI	DIQMTQSPSSLSASVGDRTITC		WYQQKPGKAPKLLIY	
RVL <sub>a</sub>	DIQMTQSPSSLSASVGDRTITC	RASEIIYSYLA	WYQQKPGKAPKLLIY	
RVL <sub>b</sub>	-----	-----	-----	
	FR1	CDR1	FR2	
	5	6	7	8
	0123456	78901234567890123456789012345678	901234567	
WS-4L	NAKTLAD	GVSSRFSGSGSGTQFSLRISSLPEDFGSYVC	QHHFGFPRT	
REI		GVPSRFSGSGSGTDFTFTISSLPEDIATYYC		
RVL <sub>a</sub>	NAKTLAD	GVPSRFSGSGSGTDFTFTISSLPEDIATYYC	QHHFGFPRT	
RVL <sub>b</sub>	-----	-----Y-----	-----	
	CDR2	FR3	CDR3	
	10			
	8901234567			
WS-4L	FCGGTKLELK			
REI	FCGGTKVEIK			
RVL <sub>a</sub>	FCGGTKVEIK			
RVL <sub>b</sub>	-----			
	FR4			



Note: FR of REI is found in reshaped human CAMPATH-1H antibody (Riechmann, et al., 1988). The five underlined amino acids in the FR of REI are amino acids that differ from the amino acid sequence of human REI. Amino acids are designated using the single letter code. Amino acid numbers are in accordance with the definition of Kabat et al.

The FR in the H chain V region of mouse WS-4 antibody most closely resemble the human H chain V region belonging to subgroup III (Table 1).

In a comparison with known human H chain V regions, the H chain V region of mouse WS-4 antibody most closely resembled the H chain V region of human antibody VDH26, a member of subgroup III of the human H chain V region, from FR1 to FR3 (Buluwela, L. et al., EMBO J., 7, 2003-2010, 1988). With respect to FR4, since the FR4 sequence of VDH26 was not reported, it was decided to use the amino acid sequence of FR4 of human antibody 4B4 belonging to subgroup III (Sanz, I. et al., J. Immunol., 142, 883-887, 1989). These human H chain V regions were used as the basis for designing the H chain V region of reshaped human WS-4 antibody.

Eight versions of the H chain V region of reshaped human WS-4 antibody were designed. In all eight versions, human FR1, FR2 and FR3 were based on FR1, FR2 and FR3 of human antibody VDH26, while FR4 was based on FR4 of human antibody 4B4. Mouse CDR was identical to the CDR of the H chain V region of mouse WS-4 antibody.

Tables 3 and 4 show the respective amino acid sequences of the H chain V region of mouse WS-4 antibody, the template FR1 through FR3 of human antibody VDH26, FR4 of human antibody 4B4, and the 8 versions of the H chain V region of reshaped human WS-4 antibody.



Table 3 Design of H Chain V Region of  
Reshaped Human WS-4 Antibody  
(Followed by Table 4)

	1	2	3	
	123456789012345678901234567890	12345		
WS-4H	EVKLVEGGGLIQPGDSLRLSCVTSGFTFS	DYYLS		
VDH26	EVQLLESGGGLVOPGGSLRLSCAASGFTFS			
RVHa~h	EVQLLESGGGLVOPGGSLRLSCAASGFTFS	DYYLS		
	FR1	CDR1		
	4	5	6	
	67890123456789	012ABC3456789012345		
WS-4H	WVROP PGKALEWVG	LIRNKANGYTREYSASVKG		
VDH26	WVRQAQGGKLELVG			
RVHa	WVRQAQGGKLELVG	LIRNKANGYTREYSASVKG		
RVHb	-----W--	-----		
RVHc	-----P-----	-----		
RVHd	-----P-----W--	-----		
RVHe	-----PP-----W--	-----		
RVHf	-----P--A--W--	-----		
RVHg	-----P-----W--	-----		
RVHh	-----W--	-----		
	FR2	CDR2		



Table 4 Design of H Chain V Region of Reshaped Human WS-4  
(Following on Table 3)

	7	8	9	10
	67890123456789012ABC345678901234			567890ABC12.
WS-4H	RFTISRDDSQSILYLQMNILRGEDSATYYCAR			ENYRYDVELAY
VDH26	RLTISRREDSKNTLYLQMSLKTEDLAVYYCAR			
RVHa	RLTISRREDSKNTLYLQMSLKTEDLAVYYCAR			ENYRYDVELAY
RVHb	-----			-----
RVHc	-----			-----
RVHd	-----			-----
RVHe	-----			-----
RVHf	-----			-----
RVHg	-F-----			-----
RVHh	-F-----			-----

FR3

CDR3

11

	34567890123
WS-4H	WGQGLVTVSA
4B4	WGQGLVTVSS
RVHa~h	WGQGLVTVSS

FR4



Note: RVHa-h indicates RVHa, RVHb, RVHc, RVHd, RVHe, RVHf, RVHg and RVHh.

5 Amino acids are designated using the single letter code. Amino acid numbers are in accordance with the definition of Kabat et al.

Preparation of DNA Coding for V Region of Reshaped Human WS-4 Antibody

10 Preparation of the V region of reshaped human WS-4 antibody is described in detail in Example 5.

DNAs that code for the respective first versions of the L chain and H chain V regions of reshaped human WS-4 antibody were synthesized. It was then confirmed that the entire DNA sequence of version "a" of the L chain and H chain V regions of reshaped human WS-4 antibody codes for the correct amino acid sequence by sequence determination. The sequence of version "a" of the L chain V region of reshaped human WS-4 antibody is shown in SEQ ID NO: 62, while the sequence of version "a" of the H chain V region of reshaped human WS-4 antibody is shown in SEQ ID NO: 38.

20 DNAs that code for other versions of V region of reshaped human WS-4 antibody were prepared using a slight variation of the publicly disclosed PCR-mutation induction method (Kammann, M. et al., Nucleic Acids Res., 17, 5404, 1989) with the first version "a" as the template. As previously described in relation to the design of the V region of the reshaped human WS-4 antibody, DNA that codes for one additional version of the L chain V region of reshaped human WS-4 antibody (version "b"), as well as DNA that code for seven additional versions of the H chain V region of reshaped human WS-4 antibody (versions "b", "c", "d", "e", "f", "g" and "h") were prepared.

30 These additional versions contained slight changes in a series of amino acid sequences from the first version, and these changes in the amino acid sequences were achieved by making slight changes in the DNA sequence using PCR mutation induction. A PCR primer was designed that



introduces the required change in the DNA sequence. After a series of PCR reactions, the PCR product was cloned followed by sequence determination to confirm that the changes in the DNA sequence had occurred as designed. The sequence of version "b" of the L chain V region of reshaped human WS-4 antibody is shown in SEQ ID NO: 65, while the sequences of versions "b", "c", "d", "e", "f", "g" and "h" of the H chain V region of reshaped human WS-4 antibody are shown in SEQ ID Nos: 41, 44, 45, 48, 51, 54 and 55, respectively.

After confirming the DNA sequences of various versions of the V region of reshaped human WS-4 antibody by sequence determination, the DNAs that code for the V region of reshaped human WS-4 antibody were subcloned to mammalian cell expression vectors that already contain DNA that codes for the human C region. Namely, DNA that codes for the V chain L region of reshaped human WS-4 antibody was linked to a DNA sequence that codes for human L chain C region, while DNA that codes for the H chain V region of reshaped human WS-4 antibody was linked to a DNA sequence that codes for the human C $\gamma$ 1 region.

Next, all combinations of version "a" or "b" of the reshaped human L chain V region, and versions "a" through "h" of the H chain V region were tested for binding to human IL-8. As a result, as is shown in Fig. 7, both reshaped human antibodies containing L chain version "a" or "b" and H chain version "g" (RVLa/RVHg and RVLb/RVHg) demonstrated the ability to bind to human IL-8 to the same extent as chimeric WS-4 antibody.

Any expression system, including eukaryotic cells such as animal cells or established mammalian cells, fungus cells, yeast cells and procaryotic cells such as bacterial cells (e.g. Escherichia coli) can be used for producing the chimeric antibody or reshaped human antibody against human IL-8 of the present invention. Preferably, however, the chimeric antibody or reshaped antibody of the present invention is expressed in mammalian cells, such as COS



cells or CHO cells. In these cases, a useful, commonly used promoter can be used to express in mammalian cells. For example, it is preferable to use the human cytomegalovirus immediate early (HCMV) promoter. Examples of expression vectors that contain HCMV promoter include HCMV-VH-HCY1 and HCMV-VL-HCK, as well as those derived from pSV2neo (International Patent Application Publication No. WO92-19759) are also included.

In addition, examples of other promoters of genetic expression in mammalian cells that can be used in the present invention that should be used include virus promoters such as retrovirus, polioma virus, adenovirus and simian virus 40 (SV40), as well as promoters originating in mammalian cells such as human polypeptide chain elongation factor-1 $\alpha$  (HEF-1 $\alpha$ ). For example, in the case of using SV40 promoter, expression can be performed by following the method of Mulligan, R.C. et al. (Nature, 277, 108-114, 1979) or in the case of using HEF-1 $\alpha$  promoter, expression can be performed by following the method of Mizushima, S. et al. (Nucleic Acids Res., 18, 5322, 1990).

Another specific example of a useful promoter for the present invention is HEF-1 $\alpha$  promoter. HEF-VH-gy1 and HEF-VL-gK (Fig. 1) are contained in an expression vector containing this promoter. DNA sequences originating in polyoma virus, adenovirus, SV40 or bovine papilloma virus (BPV) and so forth can be used as replicator points. Moreover, in order to amplify the number of genetic copies in the host cells, aminoglucoside-3'-phosphotransferase, neo-resistant gene, thymidine kinase (TK) gene, E. coli xanthin-guanine phosphoribosyl-transferase (XGPRT) gene or dihydrofolate reductase (dhfr) can be used as selection markers.

In summary, the present invention first provides an L chain V region and H chain V region of mouse monoclonal antibody against human IL-8, as well as DNA that codes for said L chain V region and DNA that codes for said H chain V region. These are useful in the preparation of human/mouse



chimeric antibody and reshaped human antibody to human IL-8. An example of monoclonal antibody is WS-4. The L chain V region has the amino acid sequence shown in, for example, SEQ ID NO: 26, while the H chain V region has the amino acid sequence shown, for example, in SEQ ID NO: 27. These amino acid sequences are coded for by nucleotide sequences shown, for example, in SEQ ID Nos: 26 and 27, respectively.

The chimeric antibody against human IL-8 of the present invention comprises:

- (1) a human L chain C region and mouse L chain V region; and,
- (2) a human H chain C region and mouse H chain V region.

The mouse L chain V region, mouse H chain V region and DNAs that code for these are as previously described. The above-mentioned human L chain C region can be any human L chain C region, examples of which include the human C $\kappa$  and C $\lambda$  regions. The above-mentioned human H chain C region can be any human H chain C region, examples of which include the human C $\gamma$ 1, C $\gamma$ 2, C $\gamma$ 3 or C $\gamma$ 4 region (Ellison, J. et al., DNA, 1, 11-18 (1981), Takahashi, N. et al., Cell, 29, 671-679 (1982), and Krawinkel, U. et al., EMBO J., 1, 403-407 (1982)).

Two types of expression vectors are prepared for producing chimeric antibody. Namely, an expression vector that contains DNA that codes for the mouse L chain V region and human L chain C region under the control of an enhancer/promoter type of expression control region, and an expression vector that contains DNA that codes for the mouse H chain V region and human H chain C region under the control of an enhancer/promoter type of expression control region. Next, host cells in the manner of mammalian cells are simultaneously transformed with these expression vectors, and the transformed cells are cultured either in vitro or in vivo to produce chimeric antibody.



Alternatively, DNA that codes for mouse L chain V region and human L chain C region and DNA that codes for mouse H chain V region and human H chain C region can be introduced into a single expression vector, host cells are transformed using said vector, and those transformed cells are then cultured either in vitro or in vivo to produce chimeric antibody.

The reshaped human WS-4 antibody of the present invention comprises:

- (A) L chains each comprising:
- (1) a human L chain C region; and,
  - (2) an L chain V region comprising a human L chain FRs, and an L chain CDRs of mouse monoclonal antibody WS-4 against human IL-8, as well as
- (B) H chains each comprising:
- (1) a human H chain C region; and,
  - (2) an H chain V region comprising a human H chain FRs, and H chain CDRs of mouse monoclonal antibody WS-4 against human IL-8.

In a preferable mode of the present invention, the above-mentioned L chain CDR is within the amino acid sequence shown in SEQ ID NO: 26, with the extents of said amino acid sequence being defined in Table 5; the above-mentioned H chain CDR is within the amino acid sequence shown in SEQ ID NO: 27, with the extents of said amino acid sequence being defined in Table 5; the above-mentioned human L chain FR is derived from REI; the above-mentioned human H chain FR1, FR2 and FR3 are derived from VDH26, and FR4 is derived from 4B4; the above-mentioned human L chain C region is the human C<sub>K</sub> region; and, the above-mentioned human H chain C region is the human C<sub>Y1</sub> region. In addition, the above-mentioned human H chain C region may be the human C<sub>Y4</sub> region, or a radioisotope may be bound instead of the above-mentioned human L chain C region and/or human H chain C region.

It is preferable to substitute a portion of the amino acid sequence of the above-mentioned human FR to prepare



reshaped human antibody that has sufficient activity with respect to a specific antigen.

In a preferable mode of the present invention, the L chain V region has the amino acid sequence shown as RVL<sub>a</sub> or RVL<sub>b</sub> in Table 2, while the H chain V region has the amino acid sequence shown as RVH<sub>a</sub>, RVH<sub>b</sub>, RVH<sub>c</sub>, RVH<sub>d</sub>, RVH<sub>e</sub>, RVH<sub>f</sub>, RVH<sub>g</sub> or RVH<sub>h</sub> in Tables 3 and 4. Moreover, the amino acid at position 41 in the H chain V region FR2 should be proline, the amino acid at said position 47 should be tryptophan, and/or the amino acid at position 67 of said FR3 should be phenylalanine, and those having the amino acid sequences shown as RVH<sub>b</sub>, RVH<sub>d</sub>, RVH<sub>e</sub>, RVH<sub>f</sub>, RVH<sub>g</sub> or RVH<sub>h</sub> are more preferable. That in which RVH<sub>g</sub> is present as the H chain V region is the most preferable.

Two types of expression vectors are prepared for production of reshaped antibody. Namely, an expression vector that contains DNA that codes for the previously defined reshaped human L chain under control by an enhancer/promoter type of expression control region, as well as another expression vector that contains DNA that codes for the previously defined reshaped human H chain under control by an enhancer/promoter type of expression control region, are prepared. Next, host cells such as mammalian cells are simultaneously transformed by these expression vectors, and the transformed cells are cultured either in vitro or in vivo to produce reshaped human antibody.

Alternatively, DNA that codes for reshaped human L chain and DNA that codes for reshaped human H chain are introduced into a single expression vector, host cells are transformed using said vector, and those transformed cells are then cultured either in vitro or in vivo to produce the target reshaped human antibody.

The chimeric antibody or reshaped human antibody produced in this manner can be isolated and purified in accordance with routine methods such as protein A affinity



chromatography, ion exchange chromatography or gel filtration.

5 The chimeric L chain or reshaped human L chain of the present invention can be used to prepare complete antibody by combining with an H chain. Similarly, the chimeric H chain or reshaped human H chain of the present invention can be used to prepare complete antibody by combining with an L chain.

10 The mouse L chain V region, reshaped human L chain V region, mouse H chain V region and reshaped human H chain V region are inherently regions that bind to antigen in the form of human IL-8. They are considered to be useful as pharmaceuticals, diagnostic drugs and so forth either alone or in the form of fused protein with other proteins.

15 In addition, the L chain V region CDR and H chain V region CDR of the present invention are also inherently portions that bind to antigen in the form of human IL-8. These are considered to be useful as pharmaceuticals, diagnostic drugs and so forth either alone or in the form of fused protein with other proteins.

20 The DNA that codes for mouse L chain V region of the present invention is useful for preparing DNA that codes for chimeric L chain, or DNA that codes for reshaped human L chain. Similarly, the DNA that codes for mouse H chain V region is useful for preparing DNA that codes for chimeric H chain or DNA that codes for reshaped human H chain. In addition, the DNA that codes for the L chain V region CDR of the present invention is useful for preparing DNA that codes for reshaped human L chain V region, or DNA that codes for reshaped human L chain.

25 Similarly, the DNA that codes for the H chain V region CDR of the present invention is useful for preparing DNA that codes for reshaped human H chain V region, and DNA that codes for reshaped human H chain. Moreover, reshaped human antibody F(ab')<sub>2</sub>, Fab or Fv, or single chain Fv that couples both Fv of the H chain and L chain, can be produced in a suitable host and used for the purposes described



above (see, for example, Bird, R.E. et al., TIBTECH, 9, 132-137, 1991).

Single chain Fv is composed by linking the H chain V region and L chain V region of reshaped human antibody to human IL-8. In this single chain Fv, the H chain V region and L chain V region are linked by a linker, and preferably a peptide linker (Huston, J.S. et al., Proc. Natl. Acad. Sci. USA, 85, 5879-5883, 1988).

The H chain V region and L chain V region of this single chain Fv may be either of the above-mentioned H chain and L chain V regions of reshaped human antibody. Specific examples of these include the H chain V regions composed of the amino acid sequences described in SEQ ID NOs: 38, 41, 44, 45, 48, 51 and 54, and single chain Fv containing an L chain V region composed of the amino acid sequences described in SEQ ID NO: 62 or 65 (see WO88-01649).

These V regions are preferably linked by a peptide linker. Examples of peptide linkers that are used include any arbitrary single chain peptide composed of, for example 12-19 residues (see WO88-09344).

DNA that codes for single chain Fv is obtained by using DNA that codes for the H chain or H chain V region and DNA that codes for the L chain or L chain V region of the above-mentioned reshaped human antibody as template, amplifying the portion of DNA that codes for those amino acid sequences that are desired using a primer pair that defines both ends by PCR, and amplifying by combining a primer pair that defines DNA that codes for a polypeptide linker along with both its ends so as to respectively link the H and L chains.

In addition, once the DNA that code for single chain Fv are prepared, an expression vector that contains them along with a host that is transformed by said expression vector can be obtained in accordance with routine methods. In addition, single chain Fv can be obtained in accordance with routine methods by using that host.



In comparison with antibody molecules, single chain Fv exhibit better permeability into tissue, and are expected to be used in imaging by labelling with a radioisotope, and as a therapeutic agent having similar functions to reshaped human antibody.

5 ELISA (Enzyme-linked immunosorbent assay), EIA (Enzyme immunoassay), RIA (radioimmunoassay) or fluorescent antibody techniques can be used to confirm the binding activity of the chimeric antibody, reshaped human antibody and its F(ab')<sub>2</sub>, Fab, Fv or single chain Fv against IL-8 of  
10 the present invention. For example, in the case of using enzyme immunoassay with chimeric antibody and reshaped human antibody, human IL-8 is added to a plate coated with anti-human IL-8 polyclonal antibody, a culture supernatant  
15 or purified sample of cells that produce chimeric antibody or reshaped human antibody against human IL-8 is added, and a suitable secondary antibody is added that is labeled with an enzyme such as alkaline phosphatase. After incubating and washing the plate, an enzyme substrate such as p-  
20 nitrophenylphosphate is added followed by measurement of absorbance to evaluate the antigen binding activity.

The IL-8 binding inhibitory activity to IL-8 receptors of the chimeric antibody, reshaped human antibody, and its F(ab')<sub>2</sub>, Fab, Fv or single chain Fv against human IL-8 is  
25 evaluated by an ordinary ligand receptor binding inhibition assay. For example, in order to assay the inhibition of binding of IL-8 to IL-8 receptors on neutrophils, after separating neutrophils obtained from heparinized blood by centrifugation or other means, a cell suspension is  
30 prepared having a suitable number of cells that can be used in the above-mentioned assay.

A solution containing IL-8 suitably labeled with <sup>125</sup>I and so forth and non-labeled IL-8 is mixed with a solution containing the antibody of the present invention or its  
35 fragments prepared at a suitable concentration, followed by the addition of this mixture to the above-mentioned neutrophil suspension. After a certain period of time, the



neutrophils are separated, and the labeled activity on the neutrophils is assayed.

5 Routine known methods, such as the method described in Grob, P.M. et al., J. Biol. Chem., 265, 8311-8316, 1990, can be used for evaluation of the inhibition of neutrophil chemotaxis by the antibody or its fragments of the present invention.

10 In the case of using a commercially available chemotaxis chamber, after diluting the antibody or its fragments of the present invention with a suitable culture medium, IL-8 is added to the chamber followed by the addition of the diluted antibody or fragments. Next, the prepared neutrophil suspension is added to the chamber and allowed to stand for a certain period of time. Since  
15 migrating neutrophils adhere to the filter installed in the chamber, the number of such neutrophils may be measured by ordinary methods such as staining or fluorescent antibody methods. In addition, measurement may also be performed by microscopic evaluation using a microscope or by automated  
20 measurement using a machine.

After sterilizing by filtration using a membrane filter, the chimeric antibody, reshaped human antibody and its F(ab')<sub>2</sub>, Fab, Fv or single chain Fv fragment against  
25 human IL-8 of the present invention can be administered as a pharmaceutical therapeutic agent preferably parenterally, by for example intravenous injection, intramuscular injection, intraperitoneal injection or subcutaneous injection, or transtracheally, by for example using a nebulizer. Although varying according to the age and  
30 symptoms of the patient, the normal dose in humans is 1-1000 mg/body, for which divided doses of 1-10 mg/kg/week can be selected.

After evaluating their purified binding activity, the chimeric antibody, reshaped human antibody and its F(ab')<sub>2</sub>,  
35 Fab, Fv or single chain Fv fragment against human IL-8 of the present invention can be prepared into a pharmaceutical therapeutic agent by methods routinely used for making



preparations of physiologically active proteins. For example, a preparation for injection consists of dissolving refined chimeric antibody, reshaped human antibody or its F(ab')<sub>2</sub>, Fab, Fv or single chain Fv fragment against human IL-8 in a solvent such as physiological saline or buffer, followed by the addition of an anti-adsorption agent such as Tween 80, gelatin or human serum albumin (HSA). Alternatively, this preparation may also be freeze-dried for dissolution and reconstitution prior to use. Examples of vehicles that can be used for freeze-drying include sugar-alcohols or sugars such as mannitol and glucose.

EXAMPLES

Although the following provides a detailed explanation of the present invention through its embodiments described below, the scope of the present invention is not limited by these examples.

Example 1: Cloning of DNA Coding for the V Region of Mouse Monoclonal Antibody against Human IL-8

DNA that codes for the variable region of mouse monoclonal antibody against human IL-8 was cloned in the manner described below.

1. Preparation of Total RNA

Total RNA was prepared from hybridoma WS-4 by modifying the cesium chloride density gradient centrifugation method of Chirgwin, J.M. et al. described in Biochemistry, 18, 5294-5299, 1979.

Namely,  $1 \times 10^7$  hybridoma WS-4 cells were completely homogenized in 25 ml of 4 M guanidine thiocyanate (Fluka). The homogenate was layered over a 5.7 M cesium chloride solution in a centrifuge tube followed by precipitation of the RNA by centrifuging for 14 hours at 20°C at 31,000 rpm in a Beckman SW40 rotor.

The RNA precipitate was washed with 80% ethanol and then dissolved in 200  $\mu$ l of 20 mM Tris-HCl (pH 7.5) containing 10 mM EDTA and 0.5% sodium N-laurylsarcosinate. After adding Proteinase (Boehringer) to a concentration of



0.5 mg/ml, the resulting mixture was incubated in a water bath for 30 minutes at 37°C. The mixture was extracted with phenol and chloroform and the RNA was precipitated with ethanol. Next, the RNA precipitate was dissolved in  
5 200 µl of 10mM Tris-HCl (pH 7.5) containing 1 mM EDTA.

2. Extraction of Messenger RNA (mRNA)

In order to extract mRNA coding for the H chain of mouse monoclonal antibody WS-4, poly(A)-positive mRNA was extracted from the total RNA obtained step 1 above  
10 using the Fast Track mRNA Isolation Kit Version 3.2 (Invitrogen) and following the procedure described in the manufacturer's instructions.

3. Synthesis of Single Stranded cDNA

Single stranded cDNA was synthesized from  
15 approximately 40 ng of the mRNA obtained in step 2 above using the cDNA Cycle Kit (Invitrogen) and following the procedure described in the instructions. The resultant product was then used to amplify cDNA that codes for mouse H chain V region. Furthermore, in order to amplify cDNA  
20 that codes for mouse L chain V region, single stranded cDNA was synthesized from approximately 10 µg of the above-mentioned total RNA.

4. Amplification of Gene Coding for Antibody Variable Region by PCR

( 25 (1) Amplification of cDNA Coding for Mouse H Chain V Region

MHV (mouse heavy variable) primers 1 to 12 shown in SEQ ID NOS: 13 to 24 and MHC (mouse heavy constant) primer shown in SEQ ID NO: 25 (Jones, S.T. et  
30 al., Bio/Technology, 9, 88-89, 1991) were used for the PCR primers. 100 µl of PCR solution containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.1 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1.5 mM MgCl<sub>2</sub>, 0.001% (w/v) gelatin, 5 units of DNA polymerase AmpliTaq (Perkin Elmer Cetus), 0.25 µM of one of  
35 the MHV primers shown in SEQ ID NOS: 13 to 24, 75 µM of the MCH primer shown in SEQ ID NO: 25, and 1.5 µl of the single stranded cDNA solution obtained in step 3 above.



PCR solutions were prepared for each of the MHV primers 1-12. After covering each solution with 50  $\mu$ l of mineral oil, it was heated in the order of 3 minutes at the initial temperature of 94°C, followed by a cycle of 1 minute at 94°C, 1 minute at 55°C and 1 minute at 72°C. After repeating this heating cycle 30 times, the reaction mixture was further incubated for 10 minutes at 72°C.

(2) Amplification of cDNA Coding for Mouse L Chain V Region

MKV (mouse kappa variable) primers 1 to 11 shown in SEQ ID NOs: 1 to 11 and MKC (mouse kappa constant) primer shown in SEQ ID NO: 12 (Jones, S.T. et al., Bio/Technology, 9, 88-89, 1991) were used for the PCR primers.

Amplification of cDNA was performed from 2.0  $\mu$ l of the single stranded cDNA obtained in step 3 above using the same method as that described for amplification of H chain V region gene in step 4 part (1) above with the exception that amplification was performed using 0.25  $\mu$ M each of the MKV primer mixtures and 3.0  $\mu$ M of MCK primer.

5. Purification and Fragmentation of PCR Product

The respective DNA fragments of the H chain V region and L chain V region amplified by PCR as described above were separated by agarose gel electrophoresis using 1.5% low melting point agarose (Sigma). Agarose pieces containing an H chain DNA fragment approximately 450 bp in length and an L chain DNA fragment approximately 400 bp in length were separately cut out and melted for 5 minutes at 65°C followed by the addition of an equal volume of 20 mM Tris-HCl (pH 7.5) containing 2 mM EDTA and 300 mM NaCl.

This mixture was extracted by phenol and chloroform, the DNA fragments were recovered by ethanol precipitation, and dissolved in 10 mM Tris-HCl (pH 7.5) containing 1 mM EDTA. Next, the fragments were digested for 3 hours at 37°C using 5 units of restriction enzyme XmaI (New England BioLabs) in 10 mM Tris-HCl (pH 7.9) containing 10 mM MgCl<sub>2</sub> and 1 mM dithiothreitol. Next, the



DNA fragments were digested for 2 hours at 37°C with 40 units of restriction enzyme SalI (Takara Shuzo), and the resulting DNA fragments were separated by agarose gel electrophoresis using 1.5% low melting point agarose (Sigma).

The agarose pieces containing DNA fragments were cut out and melted for 5 minutes at 65°C followed by the addition of an equal volume of 20 mM Tris-HCl (pH 7.5) containing 2 mM EDTA and 300 mM NaCl. This mixture was then extracted from phenol and chloroform, the DNA fragments were recovered by ethanol precipitation and dissolved in 10 mM Tris-HCl (pH 7.5) containing 1 mM EDTA.

Thus, a DNA fragment containing a gene that codes for mouse K-type L chain V region, and a DNA fragment containing a gene that codes for mouse H chain V region were respectively obtained. The above-mentioned DNA fragments both have an SalI attachment site at their 5' terminus, and an XmaI attachment site at their 3' terminus.

#### 6. Linkage and Transformation

Approximately 0.3 µg of the SalI-XmaI DNA fragment containing gene that codes for mouse kappa-type L chain V region prepared in the manner described above were mixed with approximately 0.1 µg of pUC19 vector (Takara Shuzo), prepared by digesting with SalI, XmaI and alkaline phosphatase of Escherichia coli (BAP; Takara Shuzo), for 4 hours at 16°C in a buffered reaction mixture containing 1 unit of T4 DNA ligase (Gibco BRL) and added supplemented buffer to link.

Next, 5 µl of the above-mentioned linkage mixture were added to 50 µl of competent cells of E. coli DH5α (GIBCO BRL) after which the cells were allowed to stand for 30 minutes on ice, for 1 minute at 42°C and again for 1 minute on ice. Next, 400 µl of 2 × YT medium (Molecular Cloning: A Laboratory Manual, Sambrook, et al., Cold Spring Harbor Laboratory Press, 1989) were added. After incubating for 1 hour at 37°C, the E. coli was spread onto 2 × YT agar medium (Molecular Cloning: A Laboratory



Manual, Sambrook, et al., Cold Spring Harbor Laboratory Press, 1989) containing 50 µg/ml of ampicillin (Meiji Seika) followed by incubation overnight at 37°C to obtain the E. coli transformant.

5 Subsequently, 50 µg of X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside, Takara Shuzo) were applied as selection marker at this time.

10 This transformant was incubated overnight at 37°C in 10 ml of 2 × YT medium containing 50 µg/ml of ampicillin, and plasmid DNA was prepared from this culture using the QIAGEN Plasmid Mini Kit (QIAGEN) and following the procedure described in the instructions.

15 The plasmid containing gene that codes for mouse κ-type L chain V region originating in hybridoma WS-4 obtained in this manner was named pUC-WS4-VL.

20 A plasmid containing gene that codes for mouse H chain V region derived from hybridoma WS-4 was prepared from SalI-XmaI DNA fragments by following the same method as described above with the exception of using JM109 for the E. coli competent cells. The resulting plasmid was named pUC-WS4-VH.

Example 2: Determination of DNA Nucleotide Sequence

25 The nucleotide sequence of the cDNA coding region in the above-mentioned plasmids was determined using M13 Primer RV and M13 Primer M4 (both Takara Shuzo) as sequence primers, an automated DNA sequencer (Applied Biosystems Inc.) and the Taq Dye Deoxy Terminator Cycle Sequencing Kit (Applied Biosystems Inc.) and following the protocol specified by the manufacturers. The nucleotide sequence of 30 the gene that codes for the L chain V region of mouse WS-4 antibody contained in plasmid pUC-WS4-VL is shown in SEQ ID NO: 26. In addition, the nucleotide sequence of the gene that codes for the H chain V region of mouse WS-4 antibody contained in plasmid pUC-WS4-VH is shown in SEQ ID NO: 27.

35 Example 3: Determination of CDR

The basic structure of the V regions of the L and H chains has mutual similarities, each having four framework



regions linked by three hyper variable regions, namely complementarity determining regions (CDR). Although the amino acid sequence of the framework region is relatively well preserved, the variability of the amino acid sequence of the CDR regions is extremely high (Kabat, E.A. et al., "Sequences of Proteins of Immunological Interest", US Dept. of Health and Human Services, 1991).

On the basis of this fact, the CDR were determined as shown in Table 5 by investigating their homology by attempting to match the amino acid sequence of the variable region of mouse monoclonal antibody to human IL-8 with the database of amino acid sequences of antibodies prepared by Kabat, et al.

Table 5 CDR in the L Chain V Region and H Chain V Region of Mouse WS-4 Antibody

Plasmid	Sequence Number	CDR1	CDR2	CDR3
pUC-WS4-VL	26	24-34	50-56	89-97
pUC-WS4-VH	27	31-35	50-68	101-111

Example 4: Confirmation of Expression of Cloned cDNA (Preparation of Chimeric WS-4 Antibody)

Preparation of Expression Vector

In order to prepare a vector that expresses chimeric WS-4 antibody, cDNA clones pUC-WS4-VL and pUC-WS4-VH, which code for the L chain and H chain V regions of mouse WS-4, respectively, were modified by PCR. These were then introduced into HEF expression vector (refer to that previously described, WO92-19759 and and Fig. 1).

The backward primer (SEQ ID NO: 28) for the L chain V region and the backward primer (SEQ ID NO: 29) for the H chain V region were respectively hybridized to DNA that codes for the start of the leader sequence of the V region,



and designed to have a Kozak consensus sequence (Kozak, M. et al., J. Mol. Biol., 196, 947-950, 1987) and a HindIII restriction site. The forward primer (SEQ ID NO: 30) for the L chain V region and the forward primer (SEQ ID NO: 31) for the H chain V region were hybridized to a DNA sequence that codes for the terminal of the J chain, and designed to add a splice donor sequence and BamHI restriction site.

100 µl of PCR reaction mixture containing 20 mM Tris-HCl (pH 8.2), 10 mM KCl, 6 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 1% Triton X-100, 100 µM dNTPs, 1.5 mM MgCl<sub>2</sub>, 100 pmoles of each primer, 100 ng of template DNA (pUC-VL or pUC-VH) and 2.5 U of AmpliTaq enzyme, were covered with 50 µl of mineral oil. After initially denaturing for 3 minutes at 94°C, a heating cycle consisting of 1 minute at 94°C, 1 minute at 55°C and 1 minute at 72°C was repeated 30 times followed by final incubation for 10 minutes at 72°C.

The PCR product was purified using 1.5% low melting point agarose gel followed by digestion with HindIII and BamHI. The L chain V region was cloned into HEF expression vector HEF-VL-gK, while the H chain V region was cloned into HEF expression vector HEF-VH-gyl. After determining the DNA sequences, plasmids containing the DNA fragment having the correct DNA sequence were named HEF-chWS4L-gK and HEF-chWS4H-gyl respectively.

#### Transfection into COS Cells

In order to observe the transient expression of chimeric WS-4 antibody, the above-mentioned expression vectors were tested in COS cells. HEF-chWS4L-gK and HEF-chWS4H-gyl were simultaneously transfected into COS cells by electroporation using the Gene Pulser system (BioRad). Each DNA (10 µg) was added to 0.8 ml of aliquot containing 1 × 10<sup>7</sup> cells/ml in PBS, and then pulsed at 1.5 kV with a capacitance of 25 µF.

After allowing a recovery period of 10 minutes at room temperature, the electroporated cells were suspended in 15 ml of DMEM culture medium (GIBCO) containing 5% γ-globulin-



free fetal bovine serum placed in a tissue culture dish. After incubating for 96 hours, the culture medium was collected, cell debris were removed by centrifugation, and the supernatant was then filtered with a disk filter having a pore diameter of 0.45  $\mu$ m (Gelman Science).

#### ELISA

ELISA plates for measurement of antigen binding and antibody concentration were prepared as described below. The ELISA plates for measurement of antigen binding activity were prepared in the following manner. After forming a solid layer in each well of a 96-well plate (Nunc) with 100  $\mu$ l of goat anti-human IL-8 polyclonal antibody (R & D Systems) dissolved in a solid layer of buffer at a concentration of 2  $\mu$ g/ml (0.1 M sodium bicarbonate, 0.02% sodium azide), and blocking with 200  $\mu$ l of dilution buffer (50 mM Tris-HCl (pH 7.2), 1% bovine serum albumin (BSA), 1 mM  $MgCl_2$ , 0.15 M NaCl, 0.05% Tween 20, and 0.02% sodium azide), 100  $\mu$ l of recombinant human IL-8 (Amersham) (5 ng/ml) was added.

A purified sample of chimeric antibody or culture supernatant of COS cells that expressed these was serially diluted and added to each well. Next, 100  $\mu$ l of alkaline phosphatase-labeled goat anti-human IgG antibody (TAGO) (1  $\mu$ g/ml) were added. After incubation and washing, substrate solution (1 mg/ml p-nitrophenyl-phosphate) was added followed by measurement of absorbance at 405 nm.

For measurement of antibody concentration, after forming a solid layer in the wells of a 96-well plate with 100  $\mu$ l of goat anti-human IgG antibody (TAGO) at a concentration of 1  $\mu$ g/ml and blocking, a purified sample of chimeric antibody or culture medium of COS cells that expressed these was serially diluted and added to each well. Next, 100  $\mu$ l of alkaline phosphatase-labeled goat anti-human IgG antibody (TAGO) (1  $\mu$ g/ml) was added. After incubation and washing, substrate solution (1 mg/ml p-nitrophenylphosphate) was added and absorbance was measured at 405 nm.



As a result, since the chimeric antibody WS-4 showed specific binding to IL-8, it was considered that this chimeric antibody has the correct structure of the V region of mouse monoclonal antibody WS-4 (see Fig. 2).

5 Furthermore, the Escherichia coli having above-mentioned plasmid HEF-chWS4L-gK was deposited as Escherichia coli DH5 $\alpha$  (HEF-chWS4L-gK), and the Escherichia coli having the above-mentioned plasmid HEF-chWS4H-gyl was deposited as Escherichia coli JM109 (HEF-chWS4H-gyl) at the  
10 Bioengineering Industrial Technology Research Institute of the Agency of Industrial Science and Technology (1-1-3 Higashi, Tsukuba, Ibaraki, Japan) on July 12, 1994 under the respective names FERM BP-4739 and FERM BP-4740 in accordance the provisions of the Budapest Convention.

15 Example 5: Preparation of Reshaped Human WS-4 Antibody

Preparation of the H Chain V Region of Reshaped Human WS-4 Antibody

DNA that codes for the H chain V region of reshaped  
20 human WS-4 antibody was designed in the manner described below. Complete DNA that codes for the H chain V region of reshaped human WS-4 antibody was designed so that known DNA sequences that respectively code for FR1 through FR3 of human antibody VDH26 and FR4 of human antibody 4B4 are  
25 linked to the DNA sequence that codes for the CDR of the H chain V region of mouse WS-4 antibody.

Next, a HindIII recognition site/Kozak consensus sequence and BamHI recognition site/splice donor sequence were respectively added to the 5' and 3' sides of this DNA  
30 sequence, followed by introduction into an HEF expression vector. The DNA sequence designed in this manner was then divided into four approximately equal oligonucleotides after which the secondary structure of those oligonucleotides for which there is the possibility of  
35 obstructing the assembly of these oligonucleotides were analyzed by computer.



The four oligonucleotide sequences are shown in SEQ ID NOs: 32 to 35. These oligonucleotides have lengths of 113 to 143 bases, and adjacent oligonucleotides have an overlap region mutually consisting of 20 bases. HF1 (SEQ ID NO: 32) and HF3 (SEQ ID NO: 34) of these four oligonucleotides have a sense DNA sequence, while the other HF2 (SEQ ID NO: 33) and HF4 (SEQ ID NO: 35) have an antisense DNA sequence. These oligonucleotides were synthesized by an automated DNA synthesizer (Applied Biosystems).

In addition, the method of assembly of these four oligonucleotides by PCR is illustrated in Fig. 3. Approximately 100 ng each of HF1 and HF2 as well as HF3 and HF4 were combined and added to a PCR reaction mixture having a final volume of 98  $\mu$ l and containing 2.5 U of Pfu DNA polymerase. After initially denaturing for 3 minutes at 94°C, the solutions were incubated for 2 cycles each cycle consisting of incubation for 2 minutes at 94°C, 2 minutes at 55°C and 2 minutes at 72°C.

After mutually replacing half the volume of the PCR reaction solutions, incubation was continued for an additional two cycles. After adding 100 pmoles each of RVH5' primer (SEQ ID NO: 36) and RVH3' primer (SEQ ID NO: 37) as external primers, the PCR reaction solutions were covered with 50  $\mu$ l of mineral oil. After initially denaturing for 3 minutes at 94°C, the reaction solutions were incubated for 45 cycles of 1 minute at 94°C, 1 minute at 55°C and 1 minute at 72°C, followed finally by incubation for 10 minutes at 72°C.

A DNA fragment containing approximately 450 base pairs was purified on a 1.5% low melting point agarose gel, digested with HindIII and BamHI and cloned into HEF expression vector HEF-VH-g $\gamma$ 1 (Fig. 1). After determining the DNA sequence using EF-1 primer (SEQ ID NO: 66) and HIP primer (SEQ ID NO: 67), the plasmid that contained a DNA fragment that codes for the correct amino acid sequence of the H chain V region was named HEF-RVHa-g $\gamma$ 1. The amino acid sequence and nucleotide sequence of the H chain V



region contained in this plasmid HEF-RVHa-gyl are shown in  
SEQ ID NO: 38.

Each of the versions "b", "c", "d", "e", "f", "g" and  
"h" of the H chain V region of reshaped human WS-4 antibody  
was prepared in the manner described below.

Version "b" (RVHb) was amplified by PCR using mutagen  
primers LTW1 (SEQ ID NO: 39) and LTW2 (SEQ ID NO: 40),  
designed so that leucine at position 47 was replaced by  
tryptophan, RVH5' (SEQ ID NO: 36) and RVH3' (SEQ ID NO:  
37) for the primers that define both ends, and plasmid HEF-  
RVHa-gyl as the template DNA to obtain plasmid HEF-RVHb-  
gyl. The amino acid sequence and nucleotide sequence of  
the H chain V region contained in this plasmid HEF-RVHb-gyl  
are shown in SEQ ID NO: 41.

Version "c" was amplified by PCR using mutagen primers  
QTP1 (SEQ ID NO: 42) and QTP2 (SEQ ID NO: 43), designed  
so that glutamic acid at position 41 was replaced by  
proline, and plasmid HEF-RVHa-gyl as the template DNA to  
obtain plasmid HEF-RVHc-gyl. The amino acid sequence and  
nucleotide sequence of the H chain V region contained in  
this plasmid HEF-RVHc-gyl are shown in SEQ ID NO: 44.

Version "d" was amplified by PCR using mutagen primers  
QTP1 and QTP2 and plasmid HEF-RVHb-gyl as the template DNA  
to obtain plasmid HEF-RVHd-gyl. The amino acid sequence  
and nucleotide sequence of the H chain V region contained  
in this plasmid HEF-RVHd-gyl are shown in SEQ ID NO: 45.

Version "e" was amplified by using mutagen primers  
ATP1 (SEQ ID NO: 46) and ATP2 (SEQ ID NO: 47), designed  
so that alanine at position 40 was replaced by proline, and  
plasmid HEF-RVHd-gyl as the template DNA to obtain plasmid  
HEF-RVHe-gyl. The amino acid sequence and nucleotide  
sequence of the H chain V region contained in this plasmid  
HEF-RVHe-gyl are shown in SEQ ID NO: 48.

Version "f" was amplified using mutagen primers GTA1  
(SEQ ID NO: 49) and GTA2 (SEQ ID NO: 50), designed so  
that glycine at position 44 was replaced by alanine, and  
plasmid HEF-RVHd-gyl for the template DNA to obtain plasmid



HEF-RVHf-gyl. The amino acid sequence and nucleotide sequence of the H chain V region contained in this plasmid HEF-RVHf-gyl are shown in SEQ ID NO: 51.

5 Version "g" was amplified using mutagen primers LTF1 (SEQ ID NO: 52) and LTF2 (SEQ ID NO: 53), designed so that leucine at position 67 was replaced by phenylalanine, and plasmid HEF-RVHd-gyl as the template DNA to obtain plasmid HEF-RVHg-gyl. The amino acid sequence and nucleotide sequence of the H chain V region contained in  
10 this plasmid HEF-RVHg-gyl are shown in SEQ ID NO: 54.

Version "h" was amplified using mutagen primers LTF1 and LTF2, and plasmid HEF-RVHb-gyl as the template DNA to obtain plasmid HEF-RVHh-gyl. The amino acid sequence and nucleotide sequence of the H chain V region contained in  
15 this plasmid HEF-RVHh-gyl are shown in SEQ ID NO: 55.

Preparation of L Chain V Region of Reshaped Human  
WS-4 Antibody

DNA that codes for the L chain V region of reshaped human WS-4 antibody was designed in the manner described  
20 below. Complete DNA that codes for the L chain V region of reshaped human WS-4 antibody was designed so that a DNA sequence that codes for the FR of human antibody REI is linked to the DNA sequence that codes for the CDR of the L chain V region of mouse WS-4 antibody.

25 Next, a HindIII recognition site/Kozak consensus sequence and BamHI recognition site/splice donor sequence were respectively added to the 5' and 3' sides of this DNA sequence so as to enable it to be introduced into an HEF expression vector. The DNA sequence designed in this  
30 manner was then divided into four approximately equal oligonucleotides after which the secondary structure of those oligonucleotides for which there is the possibility of obstructing the assembly of these oligonucleotides were analyzed by computer.

35 The four oligonucleotide sequences are shown in SEQ ID NOs: 56 to 59. These oligonucleotides have lengths of 106 to 124 bases, and adjacent oligonucleotides have an overlap



region mutually consisting of 19 to 23 bases. LF1 (SEQ ID NO: 56) and LF3 (SEQ ID NO: 58) of these four oligonucleotides have a sense DNA sequence, while the other LF2 (SEQ ID NO: 57) and LF4 (SEQ ID NO: 59) have an antisense DNA sequence. These oligonucleotides were synthesized using the same method as that employed for the above-mentioned HF1 through HF4.

For assembly, after initially denaturing 98 µl of a PCR mixture containing 100 ng of each of the four types of the nucleotides and 5 U of Ampli Taq for 3 minutes at 94°C, the mixture was incubated for 2 cycles, each cycle consisting of incubation for 2 minutes at 94°C, 2 minutes at 55°C and 2 minutes at 72°C. After adding 100 pmoles each of RVL5' primer (SEQ ID NO: 60) and RVL3' primer (SEQ ID NO: 61) as external primers, the PCR reaction mixture was covered with 50 µl of mineral oil. After initially denaturing for 3 minutes at 94°C, the reaction solution was incubated for 30 cycles of 1 minute at 94°C, 1 minute at 55°C and 1 minute at 72°C, followed finally by incubation for 10 minutes at 72°C (see Fig. 3).

A DNA fragment containing approximately 400 base pairs was purified using 1.5% low melting point agarose gel, digested with HindIII and BamHI and cloned into HEF expression vector HEF-VL-gK (Fig. 1). After determining the DNA sequence using EF-1 primer (SEQ ID NO: 66) and KIP primer (SEQ ID NO: 68), the plasmid that contained a DNA fragment that codes for the correct amino acid sequence of the L chain V region was named HEF-RVLa-gK. The amino acid sequence and nucleotide sequence of the L chain V region contained in this plasmid HEF-RVLa-gK are shown in SEQ ID NO: 62.

Version "b" (RVLb) was amplified by PCR using mutagen primers FTY1 (SEQ ID NO: 63) and FTY2 (SEQ ID NO: 64), designed so that phenylalanine at position 71 was replaced by tyrosine, RVL5' (SEQ ID NO: 60) and RVL3' (SEQ ID NO: 61) for the primers that define both ends, and plasmid HEF-RVLa-gK as the template DNA to obtain plasmid HEF-RVLb-gK.



The amino acid sequence and nucleotide sequence of the L chain V region contained in this plasmid HEF-RVLb-gk are shown in SEQ ID NO: 65.

5 In order to evaluate the antigen binding activity of each chain of the reshaped human WS-4 antibody, COS cells were first simultaneously transfected in the manner previously described in relation to expression vector HEF-RVLa-gk for version "a" of the L chain of reshaped human WS-4 antibody, and expression vector HEF-chWS4H-gyl for the  
10 H chain of chimeric WS-4 antibody. After collecting the culture medium as previously described, the amount of antibody produced and antigen binding activity were measured for the antibodies produced using the method described in the section on ELISA in the above Example 4.  
15 Those results are shown in Fig. 4. As shown in Fig. 4, it was confirmed that there was no difference in antigen binding activity between chimeric antibody (chL/chH), used as the positive control, and antibody consisting of a reshaped L chain and chimeric H chain (RVLa/chH).

20 At the same time, in order to evaluate the combination of expression vector HEF-chWS4L-gk for the L chain of chimeric WS-4 antibody and version "a" of the H chain of reshaped human WS-4 antibody, both were simultaneously co-transfected into COS cells and the amount of antibody  
25 produced and antigen binding activity were measured for the resulting antibody using the method described in the section on "ELISA" in the above Example 4. Antigen binding activity was not demonstrated for this antibody (chL/RVHa) (see Fig. 4).

30 As previously described, since version "a" of the L chain of reshaped human WS-4 antibody exhibited antigen binding activity equal to that of the L chain of chimeric WS-4 antibody, evaluation of each version of all reshaped H chains was performed by simultaneously transfecting COS  
35 cells with each version of the reshaped H chain and version "a" of the L chain of reshaped human WS-4 antibody (RVLa).



The result was that those antibodies having versions "b", "d", "e", "f", "g" and "h" of the reshaped H chain exhibited antigen binding activity comparable to that of chimeric WS-4 antibody (chL/chH) used as the positive control, thus indicating that this combination forms a functional antigen binding site in human antibody. However, with respect to the amount of antibody produced, all versions were produced in lesser amount than chimeric WS-4 antibody (chL/chH) with the exception of version "g" (RVHg). Furthermore, antigen binding activity was not observed in antibody having H chain version "c" (see Fig. 5).

Based on these findings, it was concluded that antibody having version "a" of the L chain of reshaped human WS-4 antibody (RVL<sub>a</sub>) and version "g" of the H chain of reshaped human WS-4 antibody reforms a functional antigen binding site that exhibits favorable antigen binding activity, and that the amount of antibody produced is comparable to chimeric WS-4 antibody (chL/chH) following simultaneous transfection into COS cells.

Next, an evaluation of version "b" of the L chain of reshaped human WS-4 antibody (RVL<sub>b</sub>) was performed by simultaneously transfecting COS cells with each version of the H chain with version "b" of the L chain of reshaped human WS-4 antibody (RVL<sub>b</sub>). The result showed that only antibody having version "g" of the H chain of reshaped human WS-4 antibody (RVL<sub>b</sub>/RVHg) exhibited antigen binding activity comparable to chimeric WS-4 antibody (chL/chH) used as the positive control, and it was concluded that this combination forms a functional antigen binding site in human antibody. In addition, with respect to amount of antibody produced, all versions were produced in lesser amount than chimeric WS-4 antibody (chL/chH) with the exception of version "g" (RVHg) (see Fig. 6).

In the above-mentioned evaluation, the two types of reshaped human antibody (RVL<sub>a</sub>/RVHg and RVL<sub>b</sub>/RVHg) that exhibited binding activity to human IL-8 and extent of



production comparable to that of chimeric WS-4 antibody (chL/chH) were respectively purified with a Protein A column, after which binding activity was evaluated accurately using the method described in the section on  
5 ELISA in Example 4. The result showed that chimeric WS-4 antibody (chL/chH), RVL<sub>a</sub>/RVH<sub>g</sub> antibody and RVL<sub>b</sub>/RVH<sub>g</sub> antibody all exhibited the same extents of binding activity (see Fig. 7).

Based on these findings, it was concluded that  
10 antibody having either version "a" (RVL<sub>a</sub>) or version "b" (RVL<sub>b</sub>) of the L chain of reshaped human WS-4 antibody and version "g" (RVH<sub>g</sub>) of the H chain of reshaped human WS-4 antibody reforms a functional antigen binding site that a level of exhibits favorable antigen binding activity, and  
15 that a level of antibody production comparable to that of chimeric WS-4 antibody (chL/chH) was exhibited following simultaneous transfection into COS cells.

The inhibitory activity on IL-8 binding to IL-8 receptors of reshaped human antibody consisting of version  
20 "a" (RVL<sub>a</sub>) of the H chain and version "g" (RVH<sub>g</sub>) of the H chain of reshaped human WS-4 antibody, or version "b" (RVL<sub>b</sub>) of said L chain and version "g" (RVH<sub>g</sub>) of said H chain, was evaluated by ligand receptor binding inhibition assay.

Approximately 100 ml of heparinized blood sample from  
25 normal subjects was layered in 35 ml aliquots onto 15 ml of Mono-Poly separation solution (ICN Biomedicals), and the human neutrophil layer was isolated by centrifugation according to the instructions provided. After washing  
30 these cells with RPMI-1640 medium containing 1% BSA, contaminating erythrocytes were removed with 150 mM ammonium chloride solution. After centrifuging, the cells were washed with RPMI-1640 medium containing 1% BSA and resuspended at a concentration of  $2 \times 10^7$  cells/ml. The  
35 neutrophil content of this cell suspension was found to be 95% or more as a result of measuring after staining smear



specimens prepared using Cytospin (Shandon) with Diff-Quik stain (Green Cross).

5 The above-mentioned neutrophil suspension was centrifuged and resuspended at a concentration of  $2 \times 10^7$  cells/ml with binding buffer (D-PBS containing 1% BSA and 0.1% sodium azide). At this time, SK2 chimeric antibody having an Fc portion identical to that of the human antibody of the present invention (see International Patent Application No. PCT/JP94/00859) and its antigen, human IL-6, were added to concentrations of approximately 50 µg/ml and approximately 40 ng/ml, respectively, and incubated for 10 30 minutes in an ice bath for the purpose of pre-saturating the Fc receptors on the neutrophils.

IL-8 radioactively labeled with  $^{125}\text{I}$  (74 TBq/mmol, 15 Amersham) and non-labeled IL-8 (Amersham) prepared by mixing in binding buffer at concentrations of 4 ng/ml each. Chimeric WS-4 antibody (chL/chH), reshaped human antibody (RVLa/RVHg and RVLb/RVHg), negative control human antibody (PAESEL + LOREI) or positive control mouse WS-4 antibody 20 was respectively diluted with binding buffer at concentrations between 2000 ng/ml and approximately 8 ng/ml in stepwise, 2-fold dilutions. 50 µl of IL-8 solution and 50 µl of each of the antibody solutions were incubated for 30 minutes in an ice bath. Next, 100 µl of the above-mentioned neutrophil suspension was added and incubation 25 was continued further for 1 hour with mixing every 15 minutes. Following incubation, the cell suspension was layered onto 200 µl of 20% saccharose solution followed by centrifugation and freezing. In order to measure the IL-8 30 bound to the cells, the cell sediment was cut away and radioactivity was measured with a gamma counter (Aroka). Those results are shown in Fig. 8.

Antibody having version "a" of the L chain (RVLa) and version "g" of the H chain (RVHg) of reshaped human WS-4 35 antibody, or version "b" of said L chain and version "g" of said H chain, was clearly shown to have binding inhibitory



activity comparable to that of chimeric antibody (chL/chH) in respect of the binding of IL-8 to IL-8 receptors.

Furthermore, the Escherichia coli having the above-mentioned plasmid HEF-RVLa-gK was deposited as Escherichia coli DH5 $\alpha$  (HEF-RVLa-gK), and the Escherichia coli containing plasmid HEF-RVHg-g $\gamma$ 1 was deposited as Escherichia coli JM109 (HEF-RVHg-g $\gamma$ 1) at the Bioengineering Industrial Technology Research Institute of the Agency of Industrial Science and Technology (1-1-3 Higashi, Tsukuba, Ibaraki, Japan) on July 12, 1994 under the respective names FERM BP-4738 and FERM BP-4741 based on the provisions of the Budapest Convention.

Reference Example 1: Preparation of Hybridoma WS-4

Hybridoma that produces anti-human IL-8 monoclonal antibody was prepared by fusing spleen cells of BALB/c mice immunized with human IL-8 and mouse myeloma cells P3x63-Ag8.653 according to routine methods using polyethylene glycol. Screening was performed using the activity of binding with human IL-8 as the criterion to establish the hybridoma WS-4 (Ko, Y.C. et al., J. Immunol. Methods, 149, 227-235, 1992).

INDUSTRIAL APPLICABILITY

The present invention provides reshaped human antibody against human IL-8, and in this antibody, the CDR of the V region of human antibody is substituted with the CDR of mouse monoclonal antibody against human IL-8. Since the majority of this reshaped human antibody is of human origin and CDR inherently having low antigenicity, the reshaped human antibody of the present invention has low antigenicity to humans, and for this reason can be expected to be useful in medical treatment.

List of Microorganisms Deposited under the Provisions of Article 13 bis of the Patent Cooperation Treaty International Deposit Authority:

Name: National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology



Address: 1-3 Higashi 1-chome, Tsukuba, Ibaraki,  
Japan

Deposit Numbers and Deposition Dates:

- 5 (1) Escherichia coli DH5 $\alpha$  (HEF-RVLa-gK)  
Deposit no.: FERM BP-4738  
Deposition date: July 12, 1994
- (2) Escherichia coli DH5 $\alpha$  (HEF-chWS4L-gK)  
Deposit no.: FERM BP-4739  
Deposition date: July 12, 1994
- 10 (3) Escherichia coli JM109 (HEF-chWS4H-gY1)  
Deposit no.: FERM BP-4740  
Deposition date: July 12, 1994
- (4) Escherichia coli JM109 (HEF-RVHg-gY1)  
Deposit no.: FERM BP-4741  
15 Deposition date: July 12, 1994

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.



SEQUENCE LISTING

SEQ ID NO: 1

SEQUENCE LENGTH: 40

SEQUENCE TYPE: Nucleic acid

5 STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MKV1

SEQUENCE

10 ACTAGTCGAC ATGAAGTTCG CTGTTAGGCT GTTGGTGGCTG 40

SEQ ID NO: 2

SEQUENCE LENGTH: 39

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

15 TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MKV2

SEQUENCE

ACTAGTCGAC ATGGAGWCAG ACACACTCCT GYTATGGGT 39

20 SEQ ID NO: 3

SEQUENCE LENGTH: 40

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

25 MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MKV3

SEQUENCE

ACTAGTCGAC ATGAGTGTGC TCACTCAGGT CCTGGSGTTG 40



SEQ ID NO: 4  
SEQUENCE LENGTH: 43  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
5 TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: MKV4  
SEQUENCE  
ACTAGTCGAC ATGAGGRCCC CTGCTCAGWT TYTTGGMWTC TTG 43  
10 SEQ ID NO: 5  
SEQUENCE LENGTH: 40  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
15 MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: MKV5  
SEQUENCE  
ACTAGTCGAC ATGGATTTC AGGTGCAGAT TWTGAGCTTC 40  
SEQ ID NO: 6  
20 SEQUENCE LENGTH: 37  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
25 NAME OF SEQUENCE: MKV6  
SEQUENCE  
ACTAGTCGAC ATGAGGTKCY YTCYTSAGYT YCTGRGG 37  
SEQ ID NO: 7



SEQUENCE LENGTH: 41  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear

5 MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: MKV7  
SEQUENCE  
ACTAGTCGAC ATGGGCWTC AAGTGGAGTC ACAKYYCAG G 41  
SEQ ID NO: 8

10 SEQUENCE LENGTH: 41  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA

15 NAME OF SEQUENCE: MKV8  
SEQUENCE  
ACTAGTCGAC ATGTGGGGAY CTKTTYCM TTTTCAATT G 41  
SEQ ID NO: 9

20 SEQUENCE LENGTH: 35  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: MKV9

25 SEQUENCE  
ACTAGTCGAC ATGGTRTCCW CASCTCAGT CCTTG 35  
SEQ ID NO: 10  
SEQUENCE LENGTH: 37



SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
5 NAME OF SEQUENCE: MKV10  
SEQUENCE  
ACTAGTCGAC ATGTATATAT GTTGTGTC TATTTCT 37  
SEQ ID NO: 11  
SEQUENCE LENGTH: 38  
10 SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: MKV11  
15 SEQUENCE  
ACTAGTCGAC ATGGAAGCCC CAGCTCAGCT TCTCTTCC 38  
SEQ ID NO: 12  
SEQUENCE LENGTH: 27  
SEQUENCE TYPE: Nucleic acid  
20 STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: MKC  
SEQUENCE  
25 GGATCCCGGG TGGATGGTGG GAAGATG 27  
SEQ ID NO: 13  
SEQUENCE LENGTH: 37  
SEQUENCE TYPE: Nucleic acid



STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: MHV1

5 SEQUENCE

ACTAGTCGAC ATGAAATGCA GCTGGGTCAT STTCTTC

37

SEQ ID NO: 14

SEQUENCE LENGTH: 36

SEQUENCE TYPE: Nucleic acid

10 STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MHV2

SEQUENCE

15 ACTAGTCGAC ATGGGATGGA GCTRTATCAT SYTCTT

36

SEQ ID NO: 15

SEQUENCE LENGTH: 37

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

20 TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MHV3

SEQUENCE

ACTAGTCGAC ATGAAGWTGT GGTAAACTG GGTTTTT

37

25 SEQ ID NO: 16

SEQUENCE LENGTH: 35

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single



TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MHV4

SEQUENCE

5 ACTAGTCGAC ATGRAC TTG GGYTCAGCTT GRTTT 35

SEQ ID NO: 17

SEQUENCE LENGTH: 40

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

10 TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MHV5

SEQUENCE

15 ACTAGTCGAC ATGGACTCCA GGCTCAATT AGTTTCCTT 40

SEQ ID NO: 18

SEQUENCE LENGTH: 37

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

20 MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MHV6

SEQUENCE

ACTAGTCGAC ATGGCTGTCY TRGSGCTRCT CTTCCTG 37

SEQ ID NO: 19

25 SEQUENCE LENGTH: 36

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear



MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MHV7

SEQUENCE

ACTAGTCGAC ATGGRATGGA GCKGRTCTT TMTCTT

36

5 SEQ ID NO: 20

SEQUENCE LENGTH: 33

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

10 MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: MHV8

SEQUENCE

ACTAGTCGAC ATGAGAGTGC TGATTCITTT GTG

33

15 SEQ ID NO: 21

SEQUENCE LENGTH: 40

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

20 NAME OF SEQUENCE: MHV9

SEQUENCE

ACTAGTCGAC ATGGMITGGG TGTGGAMCTT GCTATTCCTG

40

SEQ ID NO: 22

SEQUENCE LENGTH: 37

25 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA



NAME OF SEQUENCE: MHV10  
SEQUENCE  
ACTAGTCGAC ATGGGCAGAC TTACATTCTC ATTGCTG 37  
SEQ ID NO: 23  
5 SEQUENCE LENGTH: 38  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
10 NAME OF SEQUENCE: MHV11 /  
SEQUENCE  
ACTAGTCGAC ATGGATTTTG GGCTGATTTT TTTTATTG 38  
SEQ ID NO: 24  
SEQUENCE LENGTH: 37  
15 SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: MHV12  
20 SEQUENCE  
ACTAGTCGAC ATGATGGTGT TAAGTCTTCT GTACCTG 37  
SEQ ID NO: 25  
SEQUENCE LENGTH: 28  
SEQUENCE TYPE: Nucleic acid  
25 STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: MHC .



SEQUENCE

GGATCCCGGG CCAGTGGATA GACAGATG

28

SEQ ID NO: 26

SEQUENCE LENGTH: 382

5 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Double

TOPOLOGY: Linear

MOLECULE TYPE: cDNA

NAME OF SEQUENCE: WS4VL

10 Source

Organism: Mouse

Immediate source

Clone: pUC-WS4-VL

Characteristics: 1..60 sig peptide

15 61..382 mat peptide

Sequence

ATG AGT GTG CTC ACT CAG GTC CTG CGG TTG CTG CTG CTG TGG CTT ACA 48

Met Ser Val Leu Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr

-20 -15 -10 -5

20 GGT GCC AGA TGT GAC ATC CAG ATG ACT CAG TCT CCA GCC TCC CTA TCT 96

Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser

-1 1 5 10

GCA TCT GTG GGA GAA ACT GTC ACC ATC ACA TGT CGA GCA AGT GAG ATT 144

Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Ile

25 15 20 25

ATT TAC AGT TAT TTA GCA TGG TAT CAG CAG AAA CAG GGA AAA TCT CCT 192

Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro

30 35 40



CAG CTC CTG GTC TAT AAT GCA AAA ACC TTA GCA GAT GGT GTG TCA TCA 240  
 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Ser Ser  
 45 50 55 60  
 AGG TTC AGT CGC AGT GGA TCA GGC ACA CAG TTT TCT CTG CGG ATC AGC 288  
 5 Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Arg Ile Ser  
 65 70 75  
 AGC CTG CAG CCT GAA GAT TTT GGG AGT TAT TAC TGT CAA CAT CAT TTT 336  
 Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Phe  
 80 85 90  
 10 GGT TTT CCT CGG ACG TTC GGT GGA GGC ACC AAG CTG GAA CTC AAA C 382  
 Gly Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys  
 95 100 105

SEQ ID NO: 27

SEQUENCE LENGTH: 424

15 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Double

TOPOLOGY: Linear

MOLECULE TYPE: cDNA

NAME OF SEQUENCE: WS4VH

20 Source

Organism: Mouse

Immediate source

Clone: pUC-WS4-VH

Characteristics: 1..57 sig peptide

25 58..424 mat peptide

Sequence

ATG AAG TTG TCG TTA AAC TGC GTT TTT CTT CTG ACA CTT TTA AAT GGT 48  
 Met Lys Leu Trp Leu Asn Trp Val Phe Leu Val Thr Leu Leu Asn Gly  
 -19 -15 -10 -5



ATC CAG TGT GAG GTG AAA CTG CTG GAG TCT GGA GGA GGC TTG ATA CAG 96  
 Ile Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Ile Gln  
 -1 1 5 10  
 CCT GGG GAT TCT CTG ACA CTC TCC TGT GTA ACC TCT GGG TTC ACC TTC 144  
 5 Pro Gly Asp Ser Leu Arg Leu Ser Cys Val Thr Ser Gly Phe Thr Phe  
 15 20 25  
 AGT GAT TAC TAC CTG AGC TGG GTC CGC CAG CCT CCA GGA AAG GCA CTT 192  
 Ser Asp Tyr Tyr Leu Ser Trp Val Arg Gln Pro Pro Gly Lys Ala Leu  
 30 35 40 45  
 10 GAG TGG GTG GGT CTC ATT AGA AAC AAA GCC AAT GGT TAC ACA AGA GAG 240  
 Glu Trp Val Gly Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu  
 50 55 60  
 TAC AGT GCA TCT GTG AAG GGT CGG TTC ACC ATC TCC AGA GAT GAT TCC 288  
 Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser  
 15 65 70 75  
 CAA AGC ATC CTC TAT CTT CAA ATG AAC ACC CTG AGA GGT GAG GAC AGT 336  
 Gln Ser Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg Gly Glu Asp Ser  
 80 85 90  
 GCC ACT TAT TAC TGT GCA CGA GAG AAC TAT AGG TAC GAC GTA GAG CTT 384  
 20 Ala Thr Tyr Tyr Cys Ala Arg Glu Asn Tyr Arg Tyr Asp Val Glu Leu  
 95 100 105  
 GCT TAC TGG GGC CAA GGG ACT CTG GTC ACT CTC TCT GCA G 424  
 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala  
 110 115 120  
 25 SEQ ID NO: 28  
 SEQUENCE LENGTH: 34  
 SEQUENCE TYPE: Nucleic acid  
 STRANDEDNESS: Single  
 TOPOLOGY: Linear  
 30 MOLECULE TYPE: Synthetic DNA  
 NAME OF SEQUENCE: chVL backward primer



SEQUENCE

ACAAAGCTTC CACCATGAGT GTGCTCACTC AGGT

34

SEQ ID NO: 29

SEQUENCE LENGTH: 37

5 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: chVH backward primer

10 SEQUENCE

GATAAGCTTC CACCATGAAG TTGTGGTTAA ACTGGGT

37

SEQ ID NO: 30

SEQUENCE LENGTH: 37

SEQUENCE TYPE: Nucleic acid

15 STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: chVL forward primer

SEQUENCE

20 CTTGGATCCA CTCACGTTTG AGTCCAGCT TGGTGCC

37

SEQ ID NO: 31

SEQUENCE LENGTH: 37

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

25 TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: chVH forward primer

SEQUENCE



GTGGGATCCA CTCACCTGCA GAGACAGTGA CCAGAGT.

37

SEQ ID NO: 32

SEQUENCE LENGTH: 137

SEQUENCE TYPE: Nucleic acid

5 STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: HF1

SEQUENCE

10 TAAGCTTCCA CCATGGAGTT TGGGCTGACC TGGGTTTCC TTGTTGCTAT TTAAAGGGT 60  
GTCCAGTGTG AAGTGCAGCT GTTGCAGTCT GGGGGAGGCT TGGTCCAGCC TGGGGGTTCT 120  
CTGACACTCT CATCTGC 137

SEQ ID NO: 33

SEQUENCE LENGTH: 143

15 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: HF2

20 SEQUENCE  
GCACTGTACT CTCTTGTA ACCATTGGCT TTGTTTCTAA TGAGACCCAC CAACTCTAGC 60  
CCTTTCCCTT GAGCTTGGCG GACCCAGCTC AGGTAGTAAT CACTGAAGGT GAATCCAGAG 120  
GCAGCACATG AGAGTCTCAG AGA 143

SEQ ID NO: 34

25 SEQUENCE LENGTH: 113

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA



NAME OF SEQUENCE: HF3

SEQUENCE

TACACAAGAG AGTACAGTGC ATCTGTGAAG GGCAGACTTA CCATCTCAAG AGAAGATTCA 60  
AAGAACACGC TGTATCTGCA AATGAGCAGC CTGAAAACCG AAGACTTGGC CGT 113

5 SEQ ID NO: 35

SEQUENCE LENGTH: 117

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

10 MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: HF4

SEQUENCE

TCGGATCCAC TCACCTGAGG AGACGGTGAC CAGGGTTCCC TGGCCCCAGT AAGCAAGCTC 60  
TACGTCGTAG CGATAGTTCT CTCTAGCACA GTAATACAGG GCCAAGTCTT CGGTTTT 117

15 SEQ ID NO: 36

SEQUENCE LENGTH: 37

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

20 MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: RVH5' primer

SEQUENCE

GATAAGCTTC CACCATGGAG TTTGGGCTGA GCTGGGT 37

SEQ ID NO: 37

25 SEQUENCE LENGTH: 31

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear



MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: RVH3' primer

SEQUENCE

GTCGGATCCA CTCACCTGAG GAGACGGTGA C

31

5 SEQ ID NO: 38

SEQUENCE LENGTH: 424

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Double

TOPOLOGY: Linear

10 MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: RVHa

Source

Organism: Mouse and human

Immediate source

15 Clone: HEF-RVHa-gyl

Amino acid -19--1:leader

Amino acid 1-30:FR1

Amino acid 31-35:CDR1

Amino acid 36-49:FR2

20 Amino acid 50-68:CDR2

Amino acid 69-100:FR3

Amino acid 101-111:CDR3

Amino acid 112-122:FR4

Sequence

25 ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT GCT ATT TTA AAG GGT

48

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Leu Lys Gly

-19

-15

-10

-5



GTC CAG TGT GAA GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTC CAG 96  
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln

-1 1 5 10

CCT GGG GGT TCT CTG AGA CTC TCA TGT GCT GCC TCT GGA TTC ACC TTC 144  
5 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe

15 20 25

AGT CAT TAC TAC CTG ACC TGG GTC CGC CAA GCT CAA GGG AAA GGG CTA 192  
Ser Asp Tyr Tyr Leu Ser Trp Val Arg Gln Ala Gln Gly Lys Gly Leu

30 35 40 45

10 GAG TTG GTG GGT CTC ATT AGA AAC AAA GCC AAT GGT TAC ACA AGA GAC 240  
Glu Leu Val Gly Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu

50 55 60

TAC AGT GCA TCT GTG AAG GGC AGA CTT ACC ATC TCA AGA GAA GAT TCA 288  
Tyr Ser Ala Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Glu Asp Ser

15 65 70 75

AAG AAC ACG CTG TAT CTG CAA ATG AGC AGC CTG AAA ACC GAA GAC TTG 336  
Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu

80 85 90

GCC GTG TAT TAC TGT GCT AGA GAG AAC TAT CGC TAC GAC GTA GAG CTT 384  
20 Ala Val Tyr Tyr Cys Ala Arg Glu Asn Tyr Arg Tyr Asp Val Glu Leu

95 100 105

GCT TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G 424  
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

110 115 120

25 SEQ ID NO: 39

SEQUENCE LENGTH: 34

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

30 MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: LTW1



SEQUENCE

GGCTAGAGTG GGTGGCTCTC ATTAGAAACA AAGC

34

SEQ ID NO: 40

SEQUENCE LENGTH: 36

5 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: LTW2

10 SEQUENCE

GAGACCCACC CACTCTAGCC CTTCCTTG AGCTTG

36

SEQ ID NO: 41

SEQUENCE LENGTH: 424

SEQUENCE TYPE: Nucleic acid

15 STRANDEDNESS: Double

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: RVHb

Source

20 Organism: Mouse and human

Immediate source

Clone: HEF-RVHb-gyl

Amino acid -19--1:leader

Amino acid 1-30:FR1

25 Amino acid 31-35:CDR1

Amino acid 36-49:FR2

Amino acid 50-68:CDR2

Amino acid 69-100:FR3



Amino acid 101-111:CDR3

Amino acid 112-122:FR4

Sequence

	ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT GCT ATT TTA AAG GGT	48
5	Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Leu Lys Gly	
	-19                      -15                      -10                      -5	
	GTC CAG TGT GAA GTG CAG CTG TTG GAG TCT GGC GGA CGC TTG GTC CAG	96
	Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln	
	-1    1                      5                      10	
10	CCT GGG GGT TCT CTG AGA CTC TCA TGT GCT GCC TCT GGA TTC ACC TTC	144
	Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe	
	15                      20                      25	
	AGT GAT TAC TAC CTG AGC TGG GTC CGC CAA GCT CAA GGG AAA GGG CTA	192
	Ser Asp Tyr Tyr Leu Ser Trp Val Arg Gln Ala Gln Gly Lys Gly Leu	
15	30                      35                      40                      45	
	GAG TCG CTG GGT CTC ATT AGA AAC AAA GCC AAT GGT TAC ACA AGA GAG	240
	Glu Trp Val Gly Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu	
	50                      55                      60	
	TAC AGT GCA TCT GTG AAG GGC AGA CTT ACC ATC TCA AGA GAA GAT TCA	288
20	Tyr Ser Ala Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Glu Asp Ser	
	65                      70                      75	
	AAG AAC ACG CTG TAT CTG CAA ATG AGC AGC CTG AAA ACC GAA GAC TTG	336
	Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu	
	80                      85                      90	
25	GCC GTG TAT TAC TGT GCT AGA GAG AAC TAT CGC TAC GAC GTA GAG CTT	384
	Ala Val Tyr Tyr Cys Ala Arg Glu Asn Tyr Arg Tyr Asp Val Glu Leu	
	95                      100                      105	
	GCT TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G	424
	Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser	
30	110                      115                      120	

SEQ ID NO: 42

SEQUENCE LENGTH: 32



SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
5 NAME OF SEQUENCE: QTP1  
SEQUENCE  
TGGCTCCGCC AAGCTCCAGG GAAAGGGCTA GA 32  
SEQ ID NO: 43  
SEQUENCE LENGTH: 32  
10 SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: QTP2  
15 SEQUENCE  
TCTAGCCCTT TCCCTGGAGC TTGGCGGACC CA 32  
SEQ ID NO: 44  
SEQUENCE LENGTH: 424  
SEQUENCE TYPE: Nucleic acid  
20 STRANDEDNESS: Double  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: RVHc  
Source  
25 Organism: Mouse and human  
Immediate source  
Clone: HEF-RVHc-gyl  
Amino acid -19--1:leader



Amino acid 1-30:FR1

Amino acid 31-35:CDR1

Amino acid 36-49:FR2

Amino acid 50-68:CDR2

5 Amino acid 69-100:FR3

Amino acid 101-111:CDR3

Amino acid 112-122:FR4

Sequence

	ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT GCT ATT TTA AAG GGT	48
10	Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Leu Lys Gly	
	-19                      -15                      -10                      -5	
	GTC CAG TGT GAA GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTC CAG	96
	Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln	
	-1    1                      5                      10	
15	CCT GGG GGT TCT CTG AGA CTC TCA TGT GCT GCC TCT GGA TTC ACC TTC	144
	Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe	
	15                      20                      25	
	AGT GAT TAC TAC CTG AGC TGG GTC CGC CAA GCT CCA GGG AAA GGG CTA	192
	Ser Asp Tyr Tyr Leu Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu	
20	30                      35                      40                      45	
	GAG TTG GTG GGT CTC ATT AGA AAC AAA GCC AAT GGT TAC ACA AGA GAG	240
	Glu Leu Val Gly Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu	
	50                      55                      60	
	TAC AGT GCA TCT CTG AAG GGC AGA CTT ACC ATC TCA AGA GAA GAT TCA	288
25	Tyr Ser Ala Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Glu Asp Ser	
	65                      70                      75	
	AAG AAC ACG CTG TAT CTG CAA ATG AGC AGC CTG AAA ACC GAA GAC TTG	336
	Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu	
	80                      85                      90	



GCC GTG TAT TAC TGT GCT AGA GAG AAC TAT CGC TAC GAC GTA GAC CTT 384  
Ala Val Tyr Tyr Cys Ala Arg Glu Asn Tyr Arg Tyr Asp Val Glu Leu  
95 100 105  
GCT TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G 424  
5 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
110 115 120  
SEQ ID NO: 45  
SEQUENCE LENGTH: 424  
SEQUENCE TYPE: Nucleic acid  
10 STRANDEDNESS: Double  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: RVHd  
Source  
15 Organism: Mouse and human  
Immediate source  
Clone: HEF-RVHd-gyl  
Amino acid -19--1:leader  
Amino acid 1-30:FR1  
20 Amino acid 31-35:CDR1  
Amino acid 36-49:FR2  
Amino acid 50-68:CDR2  
Amino acid 69-100:FR3  
Amino acid 101-111:CDR3  
25 Amino acid 112-122:FR4

Sequence

ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT GCT ATT TTA AAG GGT 48  
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Leu Lys Gly  
-19 -15 -10 -5



GTC CAG TGT GAA GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTC CAG 96  
Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln  
-1 1 5 10  
CCT GGG GGT TCT CTG AGA CTC TCA TGT GCT GCC TCT GGA TTC ACC TTC 144  
5 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe  
15 20 25  
AGT GAT TAC TAC CTG AGC TGG GTC CGC CAA GCT CCA GGG AAA GGG CTA 192  
Ser Asp Tyr Tyr Leu Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu  
30 35 40 45  
10 GAG TGG GTG GGT CTC ATT AGA AAC AAA GCC AAT GGT TAC ACA AGA GAG 240  
Glu Trp Val Gly Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu  
50 55 60  
TAC AGT GCA TCT GTG AAG GGC AGA CTT ACC ATC TCA AGA GAA GAT TCA 288  
Tyr Ser Ala Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Glu Asp Ser  
15 65 70 75  
AAG AAC ACG CTG TAT CTG CAA ATG AGC AGC CTG AAA ACC GAA GAC TTG 336  
Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu  
80 85 90  
GCC GTG TAT TAC TGT GCT AGA GAG AAC TAT CGC TAC GAC GTA GAG CTT 384  
20 Ala Val Tyr Tyr Cys Ala Arg Glu Asn Tyr Arg Tyr Asp Val Glu Leu  
95 100 105  
GCT TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G 424  
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
110 115 120  
25 SEQ ID NO: 46  
SEQUENCE LENGTH: 26  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
30 MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: ATP1



SEQUENCE

TGGGTCGGCC AACCTCCAGG GAAAGG

26

SEQ ID NO: 47

SEQUENCE LENGTH: 26

5 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: ATP2

10 SEQUENCE

CCTTTCCTG GAGGTGGCG GACCCA

26

SEQ ID NO: 48

SEQUENCE LENGTH: 424

SEQUENCE TYPE: Nucleic acid

15 STRANDEDNESS: Double

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: RVHe

Source

20 Organism: Mouse and human

Immediate source

Clone: HEF-RVHe-gyl

Amino acid -19--1:leader

Amino acid 1-30:FR1

25 Amino acid 31-35:CDR1

Amino acid 36-49:FR2

Amino acid 50-68:CDR2

Amino acid 69-100:FR3



Amino acid 101-111:CDR3

Amino acid 112-122:FR4

Sequence

	ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT GCT ATT TTA AAG GGT	48
5	Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Leu Lys Gly	
	-19                      -15                      -10                      -5	
	GTC CAG TGT GAA GTG CAG CTC TTC GAG TCT GGG GGA GGC TTG GTC CAG	96
	Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln	
	-1    1                                      5                                      10	
10	CCT GGG GGT TCT CTG AGA CTC TCA TGT GCT GCC TCT GGA TTC ACC TTC	144
	Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe	
	15                                      20                                      25	
	AGT GAT TAC TAC CTG AGC TGG GTC CGC CAA CCT CCA GGG AAA GGG CTA	192
	Ser Asp Tyr Tyr Leu Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu	
15	30                                      35                                      40                                      45	
	GAG TGG GTG GGT CTC ATT AGA AAC AAA GCC AAT GGT TAC ACA AGA GAG	240
	Glu Trp Val Gly Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu	
	50                                      55                                      60	
	TAC AGT GCA TCT GTG AAG GGC AGA CTT ACC ATC TCA AGA GAA GAT TCA	288
20	Tyr Ser Ala Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Glu Asp Ser	
	65                                      70                                      75	
	AAG AAC ACG CTG TAT CTG CAA ATG AGC AGC CTG AAA ACC GAA GAC TTG	336
	Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu	
	80                                      85                                      90	
25	GCC GTG TAT TAC TGT GCT AGA GAG AAC TAT CGC TAC GAC GTA GAG CTT	384
	Ala Val Tyr Tyr Cys Ala Arg Glu Asn Tyr Arg Tyr Asp Val Glu Leu	
	95                                      100                                      105	
	GCT TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G	424
	Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser	
30	110                                      115                                      120	

SEQ ID NO: 49

SEQUENCE LENGTH: 29



SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA

5 NAME OF SEQUENCE: GTA1  
SEQUENCE  
CAAGCTCCAG GGAAAGCGCT AGAGTGGGT 29  
SEQ ID NO: 50  
SEQUENCE LENGTH: 29

10 SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: GTA2

15 SEQUENCE  
ACCCACTCTA GCGCTTTCCC TCGAGCTTG 29  
SEQ ID NO: 51  
SEQUENCE LENGTH: 424  
SEQUENCE TYPE: Nucleic acid

20 STRANDEDNESS: Double  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: RVHf  
Source

25 Organism: Mouse and human  
Immediate source  
Clone: HEP-RVHf-gyl  
Amino acid -19--1:leader



Amino acid 1-30:FR1  
 Amino acid 31-35:CDR1  
 Amino acid 36-49:FR2  
 Amino acid 50-68:CDR2  
 5 Amino acid 69-100:FR3  
 Amino acid 101-111:CDR3  
 Amino acid 112-122:FR4

Sequence

	ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT GCT ATT TTA AAG GGT	48
10	Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Leu Lys Gly	
	-19 -15 -10 -5	
	GTC CAG TGT GAA GTG CAG CTG TTG CAG TCT GGG GGA GGC TTC CTC CAG	96
	Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln	
	-1 1 5 10	
15	CCT GGG GGT TCT CTG AGA CTC TCA TGT GCT GCC TCT GGA TTC ACC TTC	144
	Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe	
	15 20 25	
	AGT GAT TAC TAC CTG AGC TGG GTC CGC CAA GCT CCA GGG AAA GCG CTA	192
	Ser Asp Tyr Tyr Leu Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Leu	
20	30 35 40 45	
	GAG TGG GTG GGT CTC ATT AGA AAC AAA GCC AAT GGT TAC ACA AGA GAG	240
	Glu Trp Val Gly Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu	
	50 55 60	
	TAC AGT GCA TCT GTG AAG GGC AGA CTT ACC ATC TCA AGA GAA GAT TCA	288
25	Tyr Ser Ala Ser Val Lys Gly Arg Leu Thr Ile Ser Arg Glu Asp Ser	
	65 70 75	
	AAG AAC ACG CTG TAT CTG CAA ATG AGC AGC CTG AAA ACC GAA GAC TTG	336
	Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu	
	80 85 90	



GCC GTG TAT TAC TGT GCT AGA GAG AAC TAT CGC TAC GAC GTA GAG CTT 384  
Ala Val Tyr Tyr Cys Ala Arg Glu Asn Tyr Arg Tyr Asp Val Glu Leu  
95 100 105  
GCT TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G 424  
5 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
110 115 120  
SEQ ID NO: 52  
SEQUENCE LENGTH: 23  
SEQUENCE TYPE: Nucleic acid  
10 STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: LTF1  
SEQUENCE  
15 GTGAAGGCCA GATTACCAT CTC 23  
SEQ ID NO: 53  
SEQUENCE LENGTH: 23  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
20 TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: LTF2  
SEQUENCE  
GAGATGGTAA ATCTGCCCTT CAC 23  
25 SEQ ID NO: 54  
SEQUENCE LENGTH: 424  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Double  
TOPOLOGY: Linear



MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: RVHg

Source

Organism: Mouse and human

5 Immediate source

Clone: HEF-RVHg-gyl

Amino acid -19--1:leader

Amino acid 1-30:FR1

Amino acid 31-35:CDR1

10 Amino acid 36-49:FR2

Amino acid 50-68:CDR2

Amino acid 69-100:FR3

Amino acid 101-111:CDR3

Amino acid 112-122:FR4

15 Sequence

ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT GCT ATT TTA AAG GGT 48

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Leu Lys Gly

-19 -15 -10 -5

GTC CAG TGT GAA GTC CAG CTG TTG GAG TCT GGG GGA GGC TTG GTC CAG 96

20 Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln

-1 1 5 10

CCT GGG GGT TCT CTG AGA CTC TCA TGT GCT GCC TCT GGA TTC ACC TTC 144

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe

15 20 25

25 AGT GAT TAC TAC CTG AGC TGG GTC CGC CAA GCT CCA GGG AAA GGG CTA 192

Ser Asp Tyr Tyr Leu Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu

30 35 40 45

GAG TGG GTG GCT CTC ATT AGA AAC AAA GCC AAT GGT TAC ACA AGA GAG 240

Glu Trp Val Gly Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu

50 55 60



TAC AGT GCA TCT GTG AAG GGC AGA TTT ACC ATC TCA AGA GAA GAT TCA 288  
Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asp Ser  
65 70 75  
AAG AAC ACG CTG TAT CTG CAA ATG AGC AGC CTG AAA ACC GAA GAC TTG 336  
5 Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu  
80 85 90  
GCC GTG TAT TAC TGT GCT AGA GAG AAC TAT CGC TAC GAC GTA GAG CTT 384  
Ala Val Tyr Tyr Cys Ala Arg Glu Asn Tyr Arg Tyr Asp Val Glu Leu  
95 100 105  
10 GCT TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G 424  
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
110 115 120

SEQ ID NO: 55

SEQUENCE LENGTH: 424

15 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Double

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: RVHh

20 Source

Organism: Mouse and human

Immediate source

Clone: HEF-RVHh-gyl

Amino acid -19--1:leader

25 Amino acid 1-30:FR1

Amino acid 31-35:CDR1

Amino acid 36-49:FR2

Amino acid 50-68:CDR2

Amino acid 69-100:FR3



Amino acid 101-111:CDR3

Amino acid 112-122:FR4

Sequence

	ATG GAG TTT GGG CTG AGC TGG GTT TTC CTT GTT GCT ATT TTA AAG GGT	48
5	Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Leu Lys Gly	
	-19                      -15                      -10                      -5	
	GTC CAG TGT CAA GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTC CAG	96
	Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln	
	-1    1                      5                      10	
10	CCT GGG GGT TCT CTG AGA CTC TCA TGT GCT GCC TCT GGA TTC ACC TTC	144
	Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe	
	15                      20                      25	
	AGT GAT TAC TAC CTG AGC TGG GTC CGC CAA GCT CAA GGG AAA GGG CTA	192
	Ser Asp Tyr Tyr Leu Ser Trp Val Arg Gln Ala Gln Gly Lys Gly Leu	
15	30                      35                      40                      45	
	GAC TGG CTC GGT CTC ATT AGA AAC AAA GCC AAT GGT TAC ACA AGA GAG	240
	Glu Trp Val Gly Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Arg Glu	
	50                      55                      60	
	TAC ACT GCA TCT CTG AAG GGC AGA TTT ACC ATC TCA AGA GAA GAT TCA	288
20	Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asp Ser	
	65                      70                      75	
	AAG AAC ACG CTG TAT CTG CAA ATG AGC AGC CTG AAA ACC GAA GAC TTG	336
	Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Leu	
	80                      85                      90	
25	GCC GTG TAT TAC TGT GCT AGA GAG AAC TAT CGC TAC GAC GTA GAG CTT	384
	Ala Val Tyr Tyr Cys Ala Arg Glu Asn Tyr Arg Tyr Asp Val Glu Leu	
	95                      100                      105	
	GCT TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G	424
	Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser	
30	110                      115                      120	

SEQ ID NO: 56

SEQUENCE LENGTH: 124



SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

5 NAME OF SEQUENCE: LF1

SEQUENCE

TTGAAGCTTC CACCATGGGA TGGAGCTGTA TCATCCTCTT CTTGGTAGCA ACAGCTACAG 60  
GTGTCCACTC CGACATCCAG ATGACCCAGA GCCCAAGCAG CCTGAGCGCC AGCGTAGGTG 120  
ACAG 124

10 SEQ ID NO: 57

SEQUENCE LENGTH: 122

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

15 MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: LF2

SEQUENCE

GCATTGTAGA TCAGCAGCTT TGGAGCCTTT CCTGGCTTCT GCTGGTACCA TGCTAAATAA 60  
CTGTAAATAA TCTCGCTTGC TCGACAGGTG ATGGTCACTC TGTACCTAC GCTGGCGCTC 120  
AG 122

20

SEQ ID NO: 58

SEQUENCE LENGTH: 121

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

25 TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: LF3

SEQUENCE



AGCTGCTGAT CTACAATGCA AAAACCTTAG CAGATGGAGT GCCAAGCAGA TTCAGCGGTA 60  
GCGGTAGCGG TACCGACTTC ACCTTCACCA TCAGCAGCCT CCAGCCAGAG GACATCGCTA 120  
C 121

SEQ ID NO: 59

5 SEQUENCE LENGTH: 106  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA

10 NAME OF SEQUENCE: LF4

SEQUENCE

GTAGGATCCA CTCACGTTTG ATTTCGACCT TGGTCCCTTG GCCGAACGTC CGAGGAAAAC 60  
CAAAATGATG TTGGCAGTAG TAGGTAGCGA TGTCCTCTGG CTGGAG 106

SEQ ID NO: 60

15 SEQUENCE LENGTH: 20  
SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA

20 NAME OF SEQUENCE: RVL5'

SEQUENCE

TTGAAGCTTC CACCATGGGA 20

SEQ ID NO: 61

SEQUENCE LENGTH: 20  
25 SEQUENCE TYPE: Nucleic acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA



NAME OF SEQUENCE: RVL'3

SEQUENCE

CTAGGATCCA CTCACGTTTG

20

SEQ ID NO: 62

5 SEQUENCE LENGTH: 379

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Double

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

10 NAME OF SEQUENCE: RVLα

Source

Organism: Mouse and human

Immediate source

Clone: HEF-RVLα-gr

15 Amino acid -19--1:leader

Amino acid 1-23:FR1

Amino acid 24-34:CDR1

Amino acid 35-49:FR2

Amino acid 50-56:CDR2

20 Amino acid 57-88:FR3

Amino acid 89-97:CDR3

Amino acid 98-107:FR4

Sequence

ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA GCT ACA GGT 48

25 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

-19 -15 -10 -5

GTC CAC TCC GAC ATC CAG ATG ACC CAG AGC CCA AGC AGC CTG AGC GCC 96

Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala

-1 1 5 10



AGC GTA GGT GAC AGA GTG ACC ATC ACC TGT CGA GCA AGC GAG ATT ATT 144  
 Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ile Ile  
 15 20 25  
 TAC AGT TAT TTA GCA TGG TAC CAG CAG AAG CCA GGA AAG GCT CCA AAG 192  
 5 Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys  
 30 35 40 45  
 CTG CTG ATC TAC AAT GCA AAA ACC TTA GCA GAT GGA GTG CCA AGC AGA 240  
 Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg  
 50 55 60  
 10 TTC AGC GGT AGC GGT AGC GGT ACC GAC TTC ACC TTC ACC ATC AGC AGC 288  
 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser  
 65 70 75  
 CTC CAG CCA GAG GAC ATC GCT ACC TAC TAC TGC CAA CAT CAT TTT GGT 336  
 Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His His Phe Gly  
 15 80 85 90  
 TTT CCT CGG ACG TTC GGC CAA GGG ACC AAG GTC GAA ATC AAA C 379  
 Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 95 100 105

SEQ ID NO: 63

20 SEQUENCE LENGTH: 38

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

25 NAME OF SEQUENCE: FTY1

SEQUENCE

AGCGGTAGCG GTACCGACTA CACCTTCACC ATCAGCAG 38

SEQ ID NO: 64

SEQUENCE LENGTH: 38

30 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single



TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: FTY2

SEQUENCE

5 CTGCTGATGG TGAAGCTGTA GTCGGTACCG CTACCGCT 38

SEQ ID NO: 65

SEQUENCE LENGTH: 379

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Double

10 TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: RVLb

Source

Organism: Mouse and human

15 Immediate source

Clone: HEF-RVLb-gk

Amino acid -19--1:leader

Amino acid 1-23:FR1

Amino acid 24-34:CDR1

20 Amino acid 35-49:FR2

Amino acid 50-56:CDR2

Amino acid 57-88:FR3

Amino acid 89-97:CDR3

Amino acid 98-107:FR4

25 Sequence

ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA GCT ACA GGT 48

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

-19

-15

-10

-5



GTC CAC TCC GAC ATC CAG ATG ACC CAG AGC CCA AGC AGC CTG AGC GCC 96  
Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala  
-1 1 5 10  
AGC GTA GGT GAC AGA GTG ACC ATC ACC TGT CGA GCA AGC GAG ATT ATT 144  
5 Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ile Ile  
15 20 25  
TAC AGT TAT TTA GCA TGG TAC CAG CAG AAG CCA GGA AAG GCT CCA AAG 192  
Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys  
30 35 40 45  
10 CTG CTG ATC TAC AAT GCA AAA ACC TTA GCA GAT GGA GTG CCA AGC AGA 240  
Leu Leu Ile Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg  
50 55 60  
TTC AGC GGT AGC GGT AGC GGT ACC GAC TAC ACC TTC ACC ATC AGC AGC 288  
Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser  
15 65 70 75  
CTC CAG CCA GAG GAC ATC GCT ACC TAC TAC TGC CAA CAT CAT TTT GGT 336  
Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His His Phe Gly  
80 85 90  
TTT CCT CGG ACG TTC GGC CAA GGC ACC AAG GTC GAA ATC AAA C 379  
20 Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
95 100 105  
SEQ ID NO: 66  
SEQUENCE LENGTH: 18  
SEQUENCE TYPE: Nucleic acid  
25 STRANDEDNESS: Single  
TOPOLOGY: Linear  
MOLECULE TYPE: Synthetic DNA  
NAME OF SEQUENCE: EF1  
SEQUENCE  
30 CAGACAGTGG TTCAAAGT 18  
SEQ ID NO: 67



SEQUENCE LENGTH: 17

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

5 MOLECULE TYPE: Synthetic DNA

NAME OF SEQUENCE: HIP

SEQUENCE

GCCCCAAAGC CAAGGTC

17

SEQ ID NO: 68

10 SEQUENCE LENGTH: 20

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: Single

TOPOLOGY: Linear

MOLECULE TYPE: Synthetic DNA

15 NAME OF SEQUENCE: KIP

SEQUENCE

AACTCAATGC TTTAGGCAAA

20



- 93 -

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A variable (V) region of a light (L) chain of an antibody to the human interleukin-8 (IL-8) having the following structure:

FR1<sup>1</sup>-CDR1<sup>1</sup>-FR2<sup>1</sup>-CDR2<sup>1</sup>-FR3<sup>1</sup>-CDR3<sup>1</sup>-FR4<sup>1</sup>

wherein CDR1<sup>1</sup>, CDR2<sup>1</sup> and CDR3<sup>1</sup> represent a set of three complementary determining regions (CDR's) comprising a set of the following amino acid sequences shown by SEQ(1):

SEQ(1) CDR1<sup>1</sup>: Arg Ala Ser Glu Ile Ile Tyr Ser Tyr Leu Ala  
CDR2<sup>1</sup>: Asn Ala Lys Thr Leu Ala Asp  
CDR3<sup>1</sup>: Gln His His Phe Gly Phe Pro Arg Thr;

or a functional equivalent thereof; and

wherein FR1<sup>1</sup>, FR2<sup>1</sup>, FR3<sup>1</sup> and FR4<sup>1</sup> represent a set of four framework regions (FR's) derived from L chain V region of a human subgroup I antibody (HSGI), or functional equivalent thereof.

2. A V region of L chain according to claim 1, wherein the HSGI is REI antibody.

3. A V region of L chain according to claim 2, wherein the FR1<sup>1</sup>, FR2<sup>1</sup>, FR3<sup>1</sup> and FR4<sup>1</sup> in the REI antibody or a functional equivalent thereof comprising a set of the following amino acid sequences shown by SEQ(2) or SEQ(3):



- 94 -

SEQ (2) FR1<sup>1</sup>: Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu  
Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr  
Cys  
FR2<sup>1</sup>: Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys  
Leu Leu Ile Tyr  
FR3<sup>1</sup>: Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser  
Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu  
Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys  
FR4<sup>1</sup>: Phe Gly Gln Gly Thr Lys Val Glu Ile Lys; or

SEQ (3) FR1<sup>1</sup>: Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu  
Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr  
Cys  
FR2<sup>1</sup>: Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys  
Leu Leu Ile Tyr  
FR3<sup>1</sup>: Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser  
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu  
Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys  
FR4<sup>1</sup>: Phe Gly Gln Gly Thr Lys Val Glu Ile Lys;

or a functional equivalent thereof.

4. A V region of L chain according to claim 1, having the amino acid sequence shown in SEQ ID NO. 62 or 65.

5. A L chain of an antibody to the human IL-8 comprising a V region according to any one of claims 1 to 4, and a constant (C) region derived from human antibody.

6. A L chain according to claim 5, wherein the C region is



- 95 -

the Cκ.

7. A V region of a heavy (H) chain of an antibody to the human interleukin-8 (IL-8) having the following structure:

FR1<sup>2</sup>-CDR1<sup>2</sup>-FR2<sup>2</sup>-CDR2<sup>2</sup>-FR3<sup>2</sup>-CDR3<sup>2</sup>-FR4<sup>2</sup>

wherein CDR1<sup>2</sup>, CDR2<sup>2</sup> and CDR3<sup>2</sup> represent a set of three complimentary determining region (CDR's) comprising a set of the following amino acid sequences shown by SEQ(4):

SEQ(4)      CDR1<sup>2</sup>:      Asp Tyr Tyr Leu Ser  
                  CDR2<sup>2</sup>:      Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr  
                                  Arg Glu Tyr Ser Ala Ser Val Lys Gly  
                  CDR3<sup>2</sup>:      Glu Asn Tyr Arg Tyr Asp Val Glu Leu Ala  
                                  Tyr;

or a functional equivalent thereof; and

wherein FR1<sup>2</sup>, FR2<sup>2</sup>, FR3<sup>2</sup> and FR4<sup>2</sup> represent a set of four framework regions (FR's) derived from H chain V region of a human subgroup III antibody (HSGIII), or functional equivalent thereof.

8. A V region of H chain according to claim 7, wherein the HSGIII is VDH26 antibody and/or 4B4 antibody.

9. A V region of H chain according to claim 8, wherein the FR1<sup>2</sup>, FR2<sup>2</sup> and FR3<sup>2</sup> in the VDH26 antibody and FR4<sup>2</sup> in the 4B4 antibody comprising a set of the following amino acid



sequences shown by SEQ(5) to SEQ(12) or a functional equivalent thereof:

SEQ(5) FR1<sup>2</sup>: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu  
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys  
Ala Ala Ser Gly Phe Thr Phe Ser  
FR2<sup>2</sup>: Trp Val Arg Gln Ala Gln Gly Lys Gly Leu Glu  
Leu Val Gly  
FR3<sup>2</sup>: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn  
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr  
Glu Asp Leu Ala Val Tyr Tyr Cys Ala Arg  
FR4<sup>2</sup>: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

SEQ(6) FR1<sup>2</sup>: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu  
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys  
Ala Ala Ser Gly Phe Thr Phe Ser  
FR2<sup>2</sup>: Trp Val Arg Gln Ala Gln Gly Lys Gly Leu Glu  
Trp Val Gly  
FR3<sup>2</sup>: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn  
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr  
Glu Asp Leu Ala Val Tyr Tyr Cys Ala Arg  
FR4<sup>2</sup>: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

SEQ(7) FR1<sup>2</sup>: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu  
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys  
Ala Ala Ser Gly Phe Thr Phe Ser  
FR2<sup>2</sup>: Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu  
Leu Val Gly  
FR3<sup>2</sup>: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn  
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr



- 97 -

Glu Asp Leu Ala Val Tyr Tyr Cys Ala Arg

FR4<sup>2</sup>: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

SEQ(8)      FRI<sup>2</sup>: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu  
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys  
Ala Ala Ser Gly Phe Thr Phe Ser

FR2<sup>2</sup>: Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu  
Trp Val Gly

FR3<sup>2</sup>: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn  
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr  
Glu Asp Leu Ala Val Tyr Tyr Cys Ala Arg

FR4<sup>2</sup>: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

SEQ(9)      FRI<sup>2</sup>: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu  
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys  
Ala Ala Ser Gly Phe Thr Phe Ser

FR2<sup>2</sup>: Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu  
Trp Val Gly

FR3<sup>2</sup>: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn  
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr  
Glu Asp Leu Ala Val Tyr Tyr Cys Ala Arg

FR4<sup>2</sup>: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

SEQ(10) FRI<sup>2</sup>: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu  
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys  
Ala Ala Ser Gly Phe Thr Phe Ser

FR2<sup>2</sup>: Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu  
Trp Val Gly

FR3<sup>2</sup>: Arg Leu Thr Ile Ser Arg Glu Asp Ser Lys Asn  
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr



- 98 -

Glu Asp Leu Ala Val Tyr Tyr Cys Ala Arg

FR4<sup>2</sup>: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

SEQ (11) FR1<sup>2</sup>: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu  
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys  
Ala Ala Ser Gly Phe Thr Phe Ser

FR2<sup>2</sup>: Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu  
Trp Val Gly

FR3<sup>2</sup>: Arg Phe Thr Ile Ser Arg Glu Asp Ser Lys Asn  
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr  
Glu Asp Leu Ala Val Tyr Tyr Cys Ala Arg

FR4<sup>2</sup>: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

SEQ (12) FR1<sup>2</sup>: Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu  
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys  
Ala Ala Ser Gly Phe Thr Phe Ser

FR2<sup>2</sup>: Trp Val Arg Gln Ala Gln Gly Lys Gly Leu Glu  
Trp Val Gly

FR3<sup>2</sup>: Arg Phe Thr Ile Ser Arg Glu Asp Ser Lys Asn  
Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr  
Glu Asp Leu Ala Val Tyr Tyr Cys Ala Arg

FR4<sup>2</sup>: Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser;

or a functional equivalent thereof.

10. A V region of H chain according to claim 7, having the  
amino acid sequence shown in SEQ ID NO. 38, 41, 44, 45, 48,  
51, 54 or 55.

11. A H chain of an antibody to the human IL-8 comprising a V



- 99 -

region according to any one of claims 7 to 10, and a constant (C) region derived from human antibody.

12. A H chain according to claim 11, wherein the C region is the C $\kappa$ .

13. An antibody to the human IL-8 comprising two L chains according to claim 5 or 6, and two H chains according to claim 11 or 12.

14. A F(ab')<sub>2</sub>, Fab, Fv or single chain Fv or fragment of an antibody according to claim 13.

15. DNA encoding a V region of a L chain according to any one of claims 1 to 4.

16. DNA encoding a L chain according to claim 5 or 6.

17. DNA encoding a V region of a H chain according to any one of claims 7 to 10.

18. DNA encoding a H chain according to claim 11 or 12.

19. A vector comprising a DNA according to claim 15 or 16.

20. A vector comprising a DNA according to claim 17 or 18.

21. A vector comprising a DNA according to claim 15 or 16, and a DNA according to claim 17 or 18.



- 100 -

22. A host cell transfected with a vector according to claim 19 and/or 20.

23. A process for production of an antibody to human IL-8, comprising the steps of: culturing host cells cotransfected with an expression vector according to claim 19 and with an expression vector according to claim 20; and

recovering a desired antibody.

24. A process for production of an antibody to human IL-8, comprising the steps of: culturing host cells transfected with an expression vector according to claim 21; and

recovering a desired antibody.

DATED this 23rd day of November, 1998.

Chugai Seiyaku Kabushiki Kaisha  
by its Patent Attorneys  
DAVIES COLLISON CAVE



Fig.1




Fig.2





Fig. 3

A

OLIGONUCLEOTIDE SYNTHESIS



B

OLIGONUCLEOTIDE SYNTHESIS




Fig.4




Fig.5




Fig.6




Fig.7




Fig.8

